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Abstract 
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA. 
Asymptomatic early cancer stages and late diagnosis leads to very low survival rates of 
pancreatic cancers, compared to other cancers. Treatment options for advanced pancreatic cancer 
are limited to chemotherapy and/or radiation therapy, as surgical removal of the cancerous tissue 
becomes impossible at later stages. Therefore, there’s a critical need for innovative and improved 
chemotherapeutic treatment of (late) pancreatic cancers. It is mandatory for successful treatment 
strategies to overcome the drug resistance associated with pancreatic cancers. Nanotechnology 
based drug formulations have been providing promising alternatives in cancer treatment due to 
their selective targeting and accumulation in tumor vasculature, which can be used for efficient 
delivery of chemotherapeutic agents to tumors and metastases.  
The research of my thesis is following the principle approach to high therapeutic efficacy 
that has been first described by Dr. Helmut Ringsdorf in 1975. However, I have extended the use 
of the Ringsdorf model from polymeric to nanoparticle-based drug carriers by exploring an iron / 
iron oxide nanoparticle based drug delivery system.  
A series of drug delivery systems have been synthesized by varying the total numbers and 
the ratio of the tumor homing peptide sequence CGKRK and the chemotherapeutic drug 
doxorubicin at the surfaces of Fe/Fe3O4-nanoparticles. The cytotoxicity of these 
nanoformulations was tested against murine pancreatic cancer cell lines (Pan02) to assess their 
therapeutic capabilities for effective treatments of pancreatic cancers. Healthy mouse fibroblast 
cells (STO) were also tested for comparison, because an effective chemotherapeutic drug has to 
be selective towards cancer cells.  
  
Optimal Experimental Design methodology was applied to identify the nanoformulation 
with the highest therapeutic activity. A statistical analysis method known as response surface 
methodology was carried out to evaluate the in-vitro cytotoxicity data, and to determine whether 
the chosen experimental parameters truly express the optimized conditions of the nanoparticle 
based drug delivery system. The overall goal was to optimize the therapeutic efficacy in 
nanoparticle-based pancreatic cancer treatment. Based on the statistical data, the most effective 
iron/iron oxide nanoparticle-based drug delivery system has been identified.  Its Fe/Fe3O4 core 
has a diameter of 20 nm. The surface of this nanoparticle is loaded with the homing sequence 
CGKRK (139-142 peptide molecules per nanoparticle surface) and the chemotherapeutic agent 
doxorubicin (156-159 molecules per surface), This nanoplatform is a promising candidate for the 
nanoparticle-based chemotherapy of pancreatic cancer.  
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Abstract 
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA. 
Asymptomatic early cancer stages and late diagnosis leads to very low survival rates of 
pancreatic cancers, compared to other cancers. Treatment options for advanced pancreatic cancer 
are limited to chemotherapy and/or radiation therapy, as surgical removal of the cancerous tissue 
becomes impossible at later stages. Therefore, there’s a critical need for innovative and improved 
chemotherapeutic treatment of (late) pancreatic cancers. It is mandatory for successful treatment 
strategies to overcome the drug resistance associated with pancreatic cancers. Nanotechnology 
based drug formulations have been providing promising alternatives in cancer treatment due to 
their selective targeting and accumulation in tumor vasculature, which can be used for efficient 
delivery of chemotherapeutic agents to tumors and metastases.  
The research of my thesis is following the principle approach to high therapeutic efficacy 
that has been first described by Dr. Helmut Ringsdorf in 1975. However, I have extended the use 
of the Ringsdorf model from polymeric to nanoparticle-based drug carriers by exploring an iron / 
iron oxide nanoparticle based drug delivery system.  
A series of drug delivery systems have been synthesized by varying the total numbers and 
the ratio of the tumor homing peptide sequence CGKRK and the chemotherapeutic drug 
doxorubicin at the surfaces of Fe/Fe3O4-nanoparticles. The cytotoxicity of these 
nanoformulations was tested against murine pancreatic cancer cell lines (Pan02) to assess their 
therapeutic capabilities for effective treatments of pancreatic cancers. Healthy mouse fibroblast 
cells (STO) were also tested for comparison, because an effective chemotherapeutic drug has to 
be selective towards cancer cells.  
  
Optimal Experimental Design methodology was applied to identify the nanoformulation 
with the highest therapeutic activity. A statistical analysis method known as response surface 
methodology was carried out to evaluate the in-vitro cytotoxicity data, and to determine whether 
the chosen experimental parameters truly express the optimized conditions of the nanoparticle 
based drug delivery system. The overall goal was to optimize the therapeutic efficacy in 
nanoparticle-based pancreatic cancer treatment. Based on the statistical data, the most effective 
iron/iron oxide nanoparticle-based drug delivery system has been identified.  Its Fe/Fe3O4 core 
has a diameter of 20 nm. The surface of this nanoparticle is loaded with the homing sequence 
CGKRK (139-142 peptide molecules per nanoparticle surface) and the chemotherapeutic agent 
doxorubicin (159 molecules per surface), This nanoplatform is a promising candidate for the 
nanoparticle-based chemotherapy of pancreatic cancer. 
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Chapter 1 -  Introduction 
1.1 Pancreatic Cancers 
Cancer is a disease caused by uncontrolled division of abnormal cells in the body. Cells 
bearing damaged DNA are known as abnormal cells which do not under go apoptosis hence led 
to the formation of new set of abnormal cells by cell division. During the propagation it also has 
the ability of invading nearby tissues as well as distant areas within the body by transporting the 
malignant cells through blood stream or lymphatic vessels.1 Spreading of the cancer within the 
body is known as metastasis. The causes of cancer are not yet understood properly and various 
genetic factors as well as life style factors such as use of tobacco, alcohol, dietary habits, certain 
infections are known to increase the risk of cancers. According to the world health organization 
7.6 million deaths were occurred worldwide due to cancers and 21 million deaths are expected in 
year 2030.2 Among the various types of cancers lung, stomach, liver and breast cancers causes 
most deaths worldwide. In the USA, cancer is the second largest cause of death and about six 
hundred thousand deaths were expected in year 2013.3 Fore mentioned cancer statistics strongly 
urges the need of effective diagnostic techniques and anticancer treatments to minimize deaths 
due to the cancers.   
Conventional cancer treatment methods include chemotherapy, radiation therapy, 
transplantation and surgery where chemotherapeutic treatments are the widely used as early 
treatment method. With the ongoing research works through out the world novel treatment 
approaches are also introduced such as targeted therapy, photodynamic therapy, hyperthermia 
etc.3 Combination of conventional and novel approaches are currently in use for effective 
treatments of cancers by medical practitioners.  
2 
 
My research work is aimed towards development of a drug delivery system for effective 
treatment of pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related 
deaths in USA.4 Some of the main risk factors associated with pancreatic cancer are smoking, 
diabetes and obesity. It is a well-known fact that early stages of pancreatic cancer are 
asymptomatic. Diagnosis at very late stages led to very low survival rates due to the cancer 
compared to other cancers. 
Due to the advancements in diagnosis and treatments, cancer survival rates have been 
improving from decades to decade while pancreatic cancer still has very low survival rates as 
shown in figure 1.1.5 Therefore, the disease is still considered largely incurable. According to the 
American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative 
survival rate is 20%, and the five-year rate is 4%. These low survival rates are attributable to the 
fact that fewer than 20% of patients' tumors are confined to the pancreas at the time of diagnosis; 
in most cases, the malignancy has already progressed to the point where surgical removal is 
impossible.  
 
Figure 1.1 Relative five year survival rates of tumors5 
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Therefore, chemotherapy and radiation therapy have become the best available methods 
for pancreatic cancer treatments. But pancreatic cancer cells show high resistance towards 
chemotherapeutic and radiation agents due to the enhanced tumor stromal components and 
disordered vasculature of tissues in tumor microenvironment, which causes very low drug 
encapsulation within the tumor compartments and make them less effective towards therapy.4,6,7 
During my research work a multifunctional drug delivery system was developed that is capable 
of targeting and delivering the therapeutic agents selectively to the pancreatic cancer cells with 
high efficacy.   
1.2 Drug Delivery 
Drug delivery is a specific method for introducing pharmaceutical components to the 
human body. Once the drugs have reached their target, their therapeutic effects have to be 
activated in order to cure or overcome the medical condition that is being treated.8 In early 
medical practices drinking plant decoctions and chewing plant materials were the primary ways 
of delivering the drugs to the body.9 But most of these methods are lacking the basic 
requirements that have to be addressed in drug delivery. Consistency and uniformity of the 
therapeutic agents are most important to lead to predictable results in therapy. This led to the 
discovery of conventional drug delivery systems that are currently in use, such as pills, tablets 
lotions etc., which are using different routes.8 Regardless of the drug or its mode of delivery, 
once it is inside the human body it undergoes a series of events before it reaches its final site of 
action, which may greatly reduces it concentration and, eventually, its effectiveness.10 Therefore, 
continuing research and development are taking place in order to design effective drug delivery 
systems. 
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According to the literature, in order to obtain maximum benefits for a specific drug, it 
should be selectively delivered to its target site at a rate and concentration that permit optimal 
activity and efficacy with a minimum side/toxic effects.11 Notari et al has reported certain 
parameters that need to be considered during the formulation of a specific drug delivery system. 
They are, 
- “Pharmacokinetics properties of the drug: such as rate of absorption, rate and 
mechanism of drug elimination, biological half-life and bioavailability for the human 
body. 
- Pharmacological properties of the drug: minimum effective therapeutic concentration, 
influence of drug peaking and desirability of steady state kinetics. 
- Toxicological properties of the drug release system: minimum toxic concentration 
and frequency and type of toxicological effects.11 
There are two main classes of drug delivery systems, which are “controlled drug release 
systems” and “targeted drug delivery systems”, which depend on the drug releasing site and its 
site of action.9 1) Controlled release systems are capable of releasing the drugs at predetermined 
rate to the blood circulation from specific sites, where it is not essentially the target site of the 
drug. 2) Targeted drug delivery systems release the drug at the site of action once it is selectively 
delivered it to exactly this site.11 In general it is advantageous to develop targeted delivery 
systems, which achieve the delivery of high concentrations of active drug components to the site 
of action. 
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1.2.1 The Ringsdorf Model for Targeted Drug Delivery Systems 
 Synthetic or natural macromolecules have been widely studied and used as polymeric 
drugs since the 1950s.12 Some of the characteristics of polymers that make them an ideal 
candidates as drug delivery modalities are biocompatibility, low toxicity, and high solubility in 
physiological medium, and finally, easy excretion from the body. Chemical properties of 
polymers facilitate the attachment of therapeutic agents via simple bond formations, which have 
contributed to their wide applications in targeted drug delivery.13 Considering these 
characteristics, Prof. Dr. Helmut Ringsdorf has suggested a generalized model in 1975 that can 
be used for the construction of polymeric drugs with high efficiency.10  
 
Figure 1.2 Schematic representation of the Ringsdorf model 
 
The Ringsdorf model considers of five main components, which are the 1) the polymeric 
backbone, 2) the spacer/cleavable linker, 3) the drug, 4) the targeting moiety and 5) the 
solubilizing agent.11 Each group has their own significance and contributes to the maximum 
efficacy of the system as one unit. Usually, the polymer can be inert or biodegradable, and a 
cleavable linker specifically attaches the drug to it. One of the most significant advantages of the 
system is the proper selection of spacer/linker, which facilitates the rate of release of the active 
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drug by hydrolysis or enzymatic cleavage at the site of action. The second most important feature 
is the ability of changing the body distribution and cell uptake mechanisms of the polymeric 
delivery vehicle by attaching a targeting ligand, which is usually specific for a particular cell 
type of a group of cells with related biological features.13 Finally, the solubilizer enhances the 
solubility of the system in aqueous media, depending on the pharmacological requirements and 
applications.11 Regardless of its simplicity, the Ringsdorf model has been a historic milestone in 
the development of polymeric drug delivery systems and has been widely studied and applied by 
many research groups since then.11  
Drug delivery systems that has been developed and used in the research work is basically 
followed the original Ringsdorf model with structural modifications in order to make the system 
more effective towards pancreatic cancer treatments. Since the late twentieth century 
nanotechnology based applications have been extensively studied and nanoformulations have 
shown promising results in drug delivery.14 Therefore metal nanoparticles are incorporated in to 
the system as an alternative to the polymeric backbone to study their efficacy as drug delivery 
components. Other important theranostic components are attached to the surface of the 
nanoparticles by chemical modifications to maintain the consistency of the system as each of 
these components play their own role in drug delivery mechanisms. Magnetic iron/iron oxide 
(Fe/Fe3O4) nanoparticles are selectively used as the nanomaterial, as monodispersed magnetic 
iron/iron oxide (Fe/Fe3O4) are successfully synthesized and used in cancer treatment methods in 
the our lab. In addition to that iron oxide nanoparticles provide straightforward surface 
modification, which facilitate the drug conjugation around the nanoparticles and shows high 
solubility in physiological media.14 Biological significances, and advantageous of using nano 
materials and specially the role of iron nanoparticles are discussed in the chapter 03.  
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1.3 Ligand Targeted Anticancer Therapy  
Chemotherapy is the use of chemical agents for the treatment of cancers and it is one of 
the most widely used methods due to the fact that they are succeeded in improving the cancer 
survival rate over the past 25 years.15 Despite their activity against cancer cells they do act on 
healthy cells causing severe side effects because cancer cells resembles many common features 
with normal cells. For example both cancer cells and hair follicles, gastrointestinal cells show 
high proliferation rates and chemotherapeutic drugs such as paclitaxel, doxorubicin can interact 
with all these cells. As a result selective toxicity of the chemotherapeutic drugs becomes limited 
towards cancer cells. Various approaches are investigating in order to develop the selective 
toxicity of the chemotherapeutic drugs which includes two main methods, (i) introduction of new 
chemotherapeutic drugs and (ii) use of antibodies or ligands that specifically bound onto the 
receptors present on the cancer cells.16 Potential of using targeting ligands is taken in to 
consideration in the Ringsdorf as well since it increase the targeting activity of the drug system. 
Ligand mediated targeting is the delivery of chemotherapeutic drugs in to the cancer cells 
or to tumor vasculature selectively by associating them with molecules that binds to the antigens 
or receptors over expressed or uniquely expressed by cancerous cells compared to the normal 
healthy tissues.15 These targeting ligands can be incorporated with the drug carrier systems, 
polymers or liposomes as well. The choice of good targeting ligand or antibody depends on 
several factors such as receptor expression, internalization methods, and immune responses to 
the antibodies or binding affinities towards the ligands etc.16 There should be high antigen or 
receptor density on the targeted cells for effective targeting activity and receptor mediated 
internalization of the drug or the drug system facilities the high drug accumulation within the 
tumor vasculature.  
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Figure 1.3 Ligand mediated targeted therapy17 
 
During the tumor propagation, blood vessels around them grow along with the tumor by 
angiogenesis, formation of blood vessels from the existing vessels in order to supply the nutrient 
and oxygen demands. Therefore, tumor blood vessels have become important therapeutic target, 
which inhibits the tumor growth by inhibiting the angiogenesis.18 Tumor blood vessels also 
express high amounts of various cell surface and extracellular matrix proteins, compared to 
normal cells. Among the vast number of ligands that are used for the targeting purposes peptide 
sequences show several advantages over others as they can be achieved in smaller sizes 
compared to antigens and large-scale synthesis using chemical methods with high specificity. 
Moreover, various types of peptide ligand receptors such as integrin receptors, thrombin 
receptors are found on the tumor cell surfaces that is the key for peptide mediated targeting of 
the cancers.19 Tumor targeting peptide ligands are successfully incorporated into drug delivery 
vehicles, such as small chemotherapeutic drugs, liposomes and inorganic nanoparticles due to 
their high specificity and efficacy with minimum side effects.20 With the fore mentioned 
advantages of using peptide sequences as targeting moieties motivates us to use short peptide 
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sequence CGKRK as the targeting ligand in the constructed drug delivery platform. 
1.4 Fe/Fe3O4 Nanoparticle Based Drug Delivery System 
Considering the factors mentioned in the original Ringsdorf model, I have carried out the 
design of a ligand mediated drug delivery platform using Fe/Fe3O4 nanoparticles as drug carrier. 
This was the first step of my thesis research. The schematic representation of the nanoplatform is 
shown in the diagram below. 
 
Figure 1.4 Schematic representation of the nanoparticle based drug delivery system 
 
This system consists of all five components mentioned in the original Ringsdorf model 
with structural variations in order to maximize its therapeutic specificity and efficacy. Fe/Fe3O4 
nanoparticles are used as the backbone of the system. Fe/Fe3O4 nanoparticles are synthesized 
from thermal decomposition of iron pentacarbonyl (Fe(CO)5) as the iron source.21 Selective air 
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oxidation of the outer layer of the Fe(0) nanoparticles causes the formation of thin adherent 
Fe3O4 layer around the core Fe(0) nanoparticles. The basic synthetic strategy for the synthesis of 
Fe(0) nanoparticles are shown below. 
 
Figure 1.5 Preparation of Fe(0) nanoparticles 
1.4.1 Surface Functionalization of the Fe/Fe3O4 Nanoparticles 
There are several important factors that need to be considered during the use of metal 
nanoparticles for applications. Most importantly, they should have good (bio)chemical stability 
and dispersibility in physiological media, which must not alter their properties while they are 
transported to the active site. They should also possess long circulation times within the blood 
stream with minimum non specific binding with other proteins present in the blood. Finally, they 
should be well excreted from the body via the renal system with minimum toxicity effects. In 
order to meet these requirements nanoparticles are conjugated or coated with various 
organic/inorganic ligands, polymeric materials or protein molecules.22 For example, when 
magnetic iron oxide nanoparticles are used in biomedical applications they are coated or 
functionalized with polymers (polyethylene glycol, dextran or chitosan), organic ligands (foliate, 
citrate or dopamine) and inorganic materials, such as SiO2.22 The outer ligand coating shields the 
magnetic iron core from the surrounding environment and it also can enhance the incorporation 
Fe(CO)5 Oleylamine HDA.HCl
   Octadecene
1800C
Fe
Oleylamine or HDA
HDA.HCl hexadecylammonium chloride
Ar
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of other therapeutic agents to the nanoparticles.  
Dopamine, a catecholamine, is widely used for the surface functionalization of magnetic 
nanoparticles due to the formation of a stable, robust anchor on the surfaces of Fe3O4 or Fe2O3 
nanoparticles by forming a five membered metallocycle with Fe (III) irons. It also facilitates the 
functionalization with other ligands of interest via the primary amine group present at the 
terminal.23 The hydrophilic nature of dopamine also makes the nanoparticles become more 
biocompatible in aqueous or physiological media. Therefore, dopamine is used as the 
solubilizing agent, as well as for the construction of spacer/cleavable linkers in the construction 
of functional nanoparticle-based systems.24 The spacer or cleavable linker can be constructed by 
introducing the maleimide moiety, which is reacting with the primary aliphatic amine of 
dopamine.25 Furthermore, this modified maleimide moiety acts as a versatile synthetic platform 
due to its dienophilic nature, making Diels-Alder reactions feasible,26 and its ability of forming 
stable C-S bonds with thiol groups and C-N bonds with primary amines of the biologically 
important molecules via Michael addition reactions.27 pH mediated hydrolysis of the dopamine-
maleimide ligands enhances the release of active drug components once they are selectively 
delivered to the tumor cells. Detailed structural and chemical significances of the use of 
dopamine and maleimides will be discussed in the chapter 03.   
A short peptide sequence with terminal cysteine amino acid, CGKRK (Cys-Gly-Lys-Arg-
Lys) is used as the targeting ligand in the constructed drug delivery system. CGKRK was first 
discovered by phage display and found to bind both neovascular endothelial cells and tumor cells 
with high affinity. The specific receptor for the CGKRK is found to be heparan sulfate, a sulfated 
polysaccharide mainly located in endothelial and tumor cells.19 Previous research work showed 
that the CGKRK peptide can be used for effective tumor targeting. Furthermore, intravenously 
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injected CGKRK recognizes the blood vessels in most tumors, but not in normal tissues. 28 
1.4.2 Doxorubicin – Chemotherapeutic Drug 
Doxorubicin is used as the chemotherapeutic agent in the constructed drug delivery 
system according to the Ringsdorf model. Doxorubicin is an anthracycline antibiotic widely used 
as chemotherapeutic agent in treatment of various cancers including breast, lung, ovaries, 
multiple myeloma, bladder and many others.29 It is also used to treat noncancerous disease 
conditions as well. Like most of the anthracyline drugs, doxorubicin interacts with DNA by 
intercalation and inhibition of the DNA replication mechanisms. Specifically it is a 
topoisomerase II inhibitor, where it prevents the relaxing of supercoiled DNA, thereby inhibiting 
DNA transcription and replication.30 
 
Figure 1.6 (a) structure of doxorubicin (b) doxorubicin intercalation in to the DNA double 
helix31 
It is also reported that doxorubicin induced apoptosis in cancer cells by formation of 
reactive oxygen species (ROS) by means of redox activity even though the exact mechanism of 
ROS mediated doxorubicin induced apoptosis remains uncertain.32 
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Doxorubicin is given to the patents intravenously as its hydrochloride salt due to the 
hydrophobic nature of the drug itself. A liposomal formulation of the drug is also available to 
minimize the side effects associated with the drug. Acute toxicity effects of doxorubicin include 
nausea, vomiting, hair loss and suppression of bone marrow. In addition to that doxorubicin 
shows dose-dependent severe cardiotoxicity, renal and hepatic toxicity on the cancer patients 
with prolonged use, it has been recently found that it also causes toxicity effects on the central 
nervous system (CNS).33 It is believed that toxic effects on the heart is basically due to the 
formation of the reactive oxygen species generated form the redox reactions of doxorubicin 
within the cells, while brain toxicity may be due to the high level of cytokines generated by 
chemotherapeutic drugs and tumors itself.28 Hoffman et al further reported that cytokines are 
signaling molecules activated upon infection due to inflammatory activities within the body, 
where they also play a role in dopamine and serotonin metabolism in the CNS. High levels of 
cytokines present in the CNS cause adverse effects on the brain, resulting in fatigue, lack of 
appetite, sleep disturbance and concentration as well.     
Due to this forementioned factors, it is vital that chemotherapeutic agents, especially 
when doxorubicin is used, need to be selectively delivered to the tumor compartments to 
minimize the adverse side effects. Incorporation or attachment of the drugs with drug delivery 
vehicles, which selectively deliver the drugs into the tumor vasculature by releasing them within 
the tumor environment, greatly reduces the adverse side effects associated with 
chemotherapeutic agents. In the constructed model, the drug is covalently bound to the 
nanoparticles via dopamine-maleimide ligands. The release of doxorubicin is achieved by the 
lower pH values present in the lysomosal/late endosomal compartments within the cancer cells.34 
Therefore, the release of free doxorubicin during the time of blood circulation is minimal due to 
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the high pH values present under these physiological conditions. 
1.5 Optimization of the Therapeutic Activity of the Nanoparticle Based Drug 
Delivery System 
Once the system is constructed, the second part of the research work was to perform cell-
based assays to determine the therapeutic efficacy of the nanoparticle-based systems. Using the 
toxicity data, the optimized composition of the system with proper ratios of doxorubicin to 
CGKRK and the optimum concentration of the drug delivery system was determined by using a 
statistical analysis method. The multivariate statistical technique, which is known as “response 
surface methodology” is used as tool to carry out these optimization processes. Experimental 
design methodology was used to plan the experiments. Then the experimental data (cell 
experiments) was analyzed using mathematical models. Based on these data, the optimized 
conditions for basically any particular process can be identified. Experimental design 
methodology is especially suited in optimizing systems that depend on several variables, and 
where no clear mathematical hypothesis exists, which can verified or falsified. Furthermore, 
experimental design methodology is the method, which requires the fewest experiments to 
optimize a system. A detailed introduction and discussion of the statistical analysis method is 
provided in the next chapter. 
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Chapter 2 -  Optimization 
One of the key objectives in any system, regardless of its nature, is the ability of getting 
the maximum in production or maximum benefits from it during the desired application. In order 
to maximize its benefits the given system is adjusted by changing the critical parameters of the 
system. This is known as the process of optimization.1 In general, this is achieved by changing 
the variables one at a time while keeping the others constant and observing the responses in order 
to obtain optimal conditions. This method is known as one-variable-at-a-time.2 This is the most 
commonly used method in many scientific studies. However, this method has several 
disadvantages, such as it does not account for the interactive effects of the variables on the 
response, and the required number of experiments is high, which ultimately increases the time 
and costs of the system.1 Therefore, more versatile optimization procedures are constructed using 
multivariate statistical techniques, which can be used to study interactive effects on the responses 
in a given system.2 Multivariate designs can be used to study critical variables simultaneously, 
which can be implemented fast and, therefore, more cost effective than applying univariate 
methods.3 Multivariate statistical analysis methods are widely in use for the optimization of 
particular system when a set of responses is influenced by more than one variable.1 The 
multivariate system that is used the most is the selection of suitable experimental parameters in 
systems, for which no straightforward mechanistic paradigm exists. For these systems, the key 
variables that need to be studied and the experimental domain, in which the optimization has to 
take place, have to be designed.4   
Optimization techniques are widely used in analytical chemistry for the optimization of 
separation, extractions etc., more than in any other chemistry disciplines. With the continuously 
growing importance, quality and demand of synthetic chemistry, specifically in drug delivery, 
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the synthetic procedures or clinical applications should be optimized in order to enhance their 
capacity of producing effective therapeutic drugs in an inexpensive manner. To date, application 
of optimal experimental design techniques in drug synthesis and drug delivery were rarely 
carried out. Their availability in literature is very limited.  
2.1 Response Surface Methodology 
Response surface methodology (RSM) was originally developed and described by Box 
and Wilson in 1951.5 By definition “RSM consists of a group of mathematical and statistical 
techniques that are based on fit of empirical models to the experimental data obtained in a 
relation to experimental design”.1 The relationship between the response and the variables is 
given by,  𝑦 = 𝑓 𝑥!, 𝑥!, 𝑥!…… 𝑥! + 𝜀      (1) 
, where y is the response, f is the function of response by independent variables x1,x2, x3….xn with 
n number of variables and 𝜀 is statistical error associated with the experiments. Optimization 
studies using RSM can be separate into three main stages, which are 
1. Determination of independent variables and their levels 
2. Selection of experimental design and prediction, verification of model equation 
3. Evaluation of response plots and determination of optimal conditions 
Detailed explanations of the steps are adapted from two journal articles, “Response 
surface methodology (RSM) as a tool for optimization in analytical chemistry” by Bezerra and 
co-workers (M.A. Bezerra, R.E. Santelli, E.P. Oliveira, L.S. Villar, L.A. Escaleira, Talanta 76 
(2008) 965–977.) and “Modeling and optimization I: Usability of response surface methodology” 
by Bas and co-workers (D. Bas, I.H. Boyaci, J. Food Eng. 78 (2007) 836). 
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2.1.1 Determination of Independent Variables and Their Levels 
The main objective is to identify the experimental domain and independent variables, 
which are involved in any given system. The experimental domain is working domain of interest, 
defined by minimum and maximum limits of the variables that are studied. On the other hand, 
independent variables are experimental factors that can be changed independently of each other, 
such as temperature, reactant concentration, reaction time etc. In a given biological or chemical 
process, the experimental response is affected by numerous variables, and it is practically 
impossible to study the effects of all parameters. Therefore, it is vital to select the parameters that 
have significant effects on the system. Preliminary screening studies have to be carried out to 
identify important variables, as well as their interactive effects on the responses of the system. 
This is usually achieved by applying factorial design. After the identification of independent 
parameters, the next step is to determine the directions that need to be changed to obtain the 
maximum response, and the levels of parameters that need to be studied. Levels of variables 
simply mean the values of the variables, for which the experiments are carried out. For example, 
temperature limits can be set to 1500C	 ± 10. Correct determination of these values truly affects 
the success of the optimization. 
Units and the range of independent variables differ from one another in a given 
experimental domain thus statistical analysis cannot be performed. Therefore, independent 
variables must be normalized into a set of coordinates applying a scale of dimensionless values, 
which are proportional to their localization in the experimental region. This process is known as 
codification. The commonly used equation for transforming real values (𝑧!) into their coded 
values (𝑥!) is, 
   𝑥! = !!!!!!∆!! 𝛽!       (2) 
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, where ∆𝑧! is the distance between the real value in the central point and real value in the highest 
or lowest level of a variable, 𝛽! is the major coded limit value in the matrix for each variable and 𝑧!! is the real value at the center point. In general, coded values are ranging from -1 to 1.  
2.1.2 Selection of Experimental Design and Prediction, Verification of Model 
Equation  
As mentioned in the introduction, the most critical step in the optimization is the 
selection of a suitable experimental design depending on the complexity of the system. The 
simplest model is a linear function for first order models, where data does not present any 
curvature. When curvatures are represented in the responses, quadratic response surfaces, such as 
three level factorial, central composite, Box-Behnken, or Doehlert design must be used. After the 
proper selection of the model, a model equation is defined to predict the interaction between 
different experimental variables. A second order model will possess the following model 
equation, 
 𝑦 = 𝛽! + 𝛽!𝑥!!!!! + 𝛽!"𝑥!𝑥!!!!!!! +   𝜀          (3) 
, where 𝛽! is the constant term, 𝑘 is the number of variables, 𝛽!   represents the coefficients of the 
linear parameters, 𝛽!" represents the coefficients of the interaction parameters, 𝑥! and 𝑥! 
represents the variables and 𝜀 is the residual associated to the experiments.  
In order to determine the responses at their critical points, quadratic terms are incorporated into 
the equation (3). So it can be represent as, 
 
 𝑦 = 𝛽! + 𝛽!𝑥!!!!! + 𝛽!!𝑥!!!!!! + 𝛽!"𝑥!𝑥!!!!!!! +   𝜀    (4) 
, where 𝛽!! represents the coefficients of the quadratic parameters. 
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In order to estimate the 𝛽 parameters, the matrix notation of the model can be constructed 
as, 
 𝑦 = xβ  +  ε          (5) 𝑦!𝑦!...𝑦!!
=
11...1
  
𝑥!!𝑥!"...𝑥!!!
  
𝑥!"𝑥!!...𝑥!!!
......      
......  
𝑥!!𝑥!!....!
  
𝛽!𝛽!...𝛽!!
+
ℇ!ℇ!...ℇ!ℇ
      (6) 
, where 𝑦 is the response vector, 𝑥 is the matrix of the chosen experiment design, 𝛽  is the vector 
constituted by the parameters and ℇ   is the residual value. Equation (5) is solved by a statistical 
method known as method of least square (MLS).5 MLS is a multiple regression analysis method, 
which uses to fit a mathematical model to a set of experimental data generating the lowest 
possible value for ℇ. After the MLS vector, 𝛽𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 parameters can be obtained as: 
 𝛽 = (𝑥!  𝑥)!!(𝑥!𝑦) = 𝐶𝑥!  𝑦        (7) 
 , where 𝐶 = (𝑥!  𝑥)!! 
This equation is used to construct the response surfaces that describe the behavior of the 
response in a given experimental domain. Computational software is normally used in this 
process. In MLS method it is assumed that errors are independent of each other with zero mean 
value and a common variance value. Therefore, the variance estimated in equation (7) is obtained 
by repetitions of the central point where 𝐶 is a square matrix value. By calculating the square 
root value of 𝐶  , the standard error for coefficient 𝛽 is obtained. The final process in this step is 
to determine whether the chosen mathematical model is fitting to the data in the studied 
experimental domain. It is evaluated using application of analysis of variance (ANOVA), where 
it compares the variation due to the changes in parameters with the variation due to random 
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errors occurred during response measurments.4 General steps carried out in ANOVA are 
described as follows. Variation of data is obtained by calculating sum of the square value of the 
deviation of each observation (𝑦!) or its replicates (𝑦!") with relation to media (𝑦) by,  
 𝑑!! = 𝑦!" − 𝑦 !         (8) 
using the above equation sum of square of deviation due to the regression (SSreg) and sum of 
square of deviation due to residual generated by the model (SSres). Summation of these values is 
equal to the total sum of squares of deviation (SStot), 
 𝑆𝑆!"! = 𝑆𝑆!"# + 𝑆𝑆!"#        (9) 
Due to the repetition of central point observation error can be associated with the repetition 
values. Therefore the sum of squares of deviation is further divided into two components as 
 𝑆𝑆!"# = 𝑆𝑆!" + 𝑆𝑆!"#         (10) 
, where 𝑆𝑆!" is the sum of squares due to pure error and 𝑆𝑆!"# is sum of square due to the lack of 
fit of the model.  
The next step is to determine the media of square (MS) depending on the respective 
degree of freedom gained for each variation (total, regression, residual or lack of fit).  
Variance of sources Sum of the square Degree of freedom Media of the square 
Regression	   𝑆𝑆!"# = 𝑦! − 𝑦 !!!!!! 	   𝑝 − 1	   𝑀𝑆!"# = 𝑆𝑆!"#𝑝 − 1	  
Residuals	   𝑆𝑆!"# = 𝑦!" − 𝑦! !!!!!! 	   𝑛 − 𝑝	   𝑀𝑆!"# = 𝑆𝑆!"#𝑛 − 𝑝	  
Lack	  of	  fit	   𝑆𝑆!"# = 𝑦! − 𝑦! !!!!!! 	   𝑚 − 𝑝	   𝑀𝑆!"# = 𝑆𝑄!"#𝑚 − 𝑝	  
Pure	  error	   𝑆𝑆!" = 𝑦!" − 𝑦! !!!!!! 	   𝑛 −𝑚	   𝑀𝑆!" = 𝑆𝑆!"𝑛 −𝑚	  
Total	   𝑆𝑆!"! = 𝑦!" − 𝑦 !!!!!! 	   𝑛 − 1	   	  
 
Table 2-1 Analysis of variance for fitted mathematical model to an experimental data set 
using multiple regression1 
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Where 𝑛!: number of observation 
 𝑚 : total number of levels in the design 
 𝑝  : number of parameter of model 
 𝑦! : estimated value by the model for the level i 
 𝑦  : overall media 
 𝑦!": replicates performed in each individual levels 
 𝑦!  : media of replicates performed in the same set of experimental conditions 
Once the regression calculations are performed, there are two ways to determine the 
fitness of the chosen mathematical model with respect to the experimental data. The first method 
is to perform a significance of regression analysis, given by the ratio between media of square 
values of regression (𝑀𝑆!!") and residual (𝑀𝑆!"#) values. The value is compared with the Fisher 
distributions (f test) for corresponding degrees of freedom values. 
 
!"!"#!"!"# ≈ 𝐹!!"#,!!"#         (11) 
If the statistical significance for the above ratio is higher than the tabulated f value, the 
mathematical model is well fitted to the experimental model. The other method is to evaluate the 
lack of fit test where it compares the ratio between media of square values of lack of fit (𝑀𝑆!"#) 
and pure error (𝑀𝑆!") with f test values. 
 
!"!"#!"!" ≈ 𝐹!!"#,!!"         (12) 
If the ratio is higher, than the tabulated data model is not fitted well to the experimental 
data and it needs to be improved by carrying out repetitive experiments.   
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2.1.3 Evaluation of Response Plots and Determination of Optimal Conditions 
The final step of the optimization process is the visualization of the predicted model 
equation by constructing the response surface plots and contour plots. The response surfaces are 
the theoretical three-dimensional representation of the response versus independent variables 
while the contour plots are two-dimensional displays of the responses over the plane of 
independent variables. For quadratic models the critical point on the response surfaces can be a 
maximum, a minimum, or a saddle. Coordinates of the critical points are calculated by means of 
the first derivative of mathematical function, which is equal to zero, 
 𝑦 = 𝑓 𝑥!, 𝑥! = 𝑏! + 𝑏!𝑥! + 𝑏!𝑥! + 𝑏!!𝑥!! + 𝑏!!𝑥!! + 𝑏!"𝑥!𝑥!   (13) 
the stationary point is calculated by solving the following equations, 
   
 !"!"! = 𝑏! + 2𝑏!!𝑥! + 𝑏!"𝑥! = 0       (14) 
 !"!"! = 𝑏! + 2𝑏!!𝑥! + 𝑏!"𝑥! = 0       (15) 
When there are three or more variables are present in the system, one or more variables are set to 
constant values in order to construct the contour plots or response surfaces. Some of the common 
response surfaces and contour plots are shown in the next diagram.    
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Figure 2.1 Some profiles of surface response generated from a quadratic model in the 
optimization of two variables. (a) maximum, (b) plateau, (c) maximum outside the 
experimental region, (d) minimum, and (e) saddle surfaces1 
 
The response surface represented in figure 5(b) is a plateau relative to variable x2, which 
indicates that the response is independent on any level of variable x2. Another interesting 
response is shown in figure (e), which is a saddle. Here, neither a minimum nor a maximum 
response is obtained. This means that the chosen variables did not represent optimal conditions. 
Therefore, careful displacement of the experimental region is carried out to obtain optimal 
conditions for the system.  
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RSM has several advantages over classical one-variable-a-time optimization such as it 
provides more information from a small number of experiments, and it is capable of evaluating 
interactions between variables and their effects on the responses2.   
The success of the optimization process is greatly relying on the selection of the proper 
experimental design. As mentioned earlier, some of the common symmetrical second order 
experimental designs are full factorial designs, Box-Behnken designs, central composite designs, 
and Doehlert design. Among these methods, Doehlert experimental design is the experimental 
design model that has been used during the research. 
2.2 Doehlert Design 
David Doehlert developed this method in 1970 as a practical and economical method that 
can be used as an alternative for second order experimental designs, such as central composite 
design or Box-Behnken designs.6 Both central composite design and Box-Behnken methods are 
symmetrical and possess characteristic orthogonal and rotatable behaviors, while the 
unsymmetrical Doehlert design is neither orthogonal nor rotatable.7 A given experimental design 
is categorized as symmetrical if it has same number of levels for each independent variable that 
is studied in the system.2 According to the original article published by David Doehlert, his 
design describes a circular domain for two variables, spherical domain for three variables and 
hyperspherical domain for variables above three with uniform space filling ability throughout the 
experimental domain.6 The characteristic features of Doehlert matrix are listed below1: 
1. Requires N number of experiments according to 𝑁 = 𝑘! + 𝑘 + 𝑐! where 𝑘  is the  
number of independent variables that are studying and 𝑐! is the replicate number of 
central point. 
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2. Each variable can be studied at different levels depending on their importance 
towards the response as well as their restrictions such as cost or instrument 
constraints etc. 
3. The intervals between its levels represent a uniform distribution thus it is originally 
named as uniform shell designs. 
4. Experimental matrix can be displaced through the experimental domain via adjacent 
points present in original matrix to obtain new experimental region.  
For two variables the Doehlert design is represented by a regular hexagon with six points 
at the hexagon and one central point. The hexagon is generated using regular simplex, which is 
an equilateral triangle, and the coordinates of the triangle represent the central point and two 
other points at the hexagon. The other points of the hexagon are obtained from subtracting every 
run in the triangle from each other. Coordinates of the regular hexagon for two variables are 
given in coded units as shown below.  
 
Run	   X1	   X2	   Subtraction	  
1	   0.0	   0.0	   	  
2	   1.0	   0.0	   	  
3	   0.5	   0.866	   	  
4	   -­‐1.0	   0.0	   1-­‐2	  
5	   -­‐0.5	   -­‐0.866	   1-­‐3	  
6	   -­‐0.5	   0.866	   3-­‐2	  
7	   0.5	   -­‐0.866	   2-­‐3	  
 
Table 2-2 Coded factor levels for two variable Doehlert design 
The real experimental values corresponding to the coded values can be obtained from the 
equation (2) mentioned in the part 2.1.1. It can be clearly seen the unsymmetrical nature of the 
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design matrix that variable X1 is studied at five levels while X2 is only studied at three levels. 
Depending on the importance of the variable studied levels can be interchanged. The graphical 
representation and possible displacement of the hexagon over the experimental region is given 
below.  
 
Figure 2.2 Graphical representation of hexagonal Doehlert design in experimental domain1 
One of the major advantages of the Doehlert matrix is its space filling ability with a 
uniform grid of points, regardless of the irregularity of the experimental domain. The 
experimental matrix can also be displaced to regions with high response values while keeping 
some of the previous experimental coordinates, which ultimately reduces the number of 
experiments required in the new experimental matrix.  Furthermore, the coded limit between the 
coordinates can be lowered in order to obtain the optimal response in the area of interest. The 
experimental matrices for three and four variables are listed below.  
Applications of Doehlert matrix in optimization have increased in recent years due to the 
efficiency and several advantages over other second order models1, 4, 6.  
A study comparing the efficiencies of Composite design, Box-Behnken Design and 
Doehlert Design in comparison has found that for any independent variable value, Doehlert 
design is the most efficient among the three systems.3 It is more practical and economical, as the 
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number of experiments need to be carried out is low and some experiments data can be re-used 
with the ability of displacement of the matrix over the experimental region.7 Since the synthesis 
of nanoplatforms for cancer treatment is time-consuming and costly, Doehlert Design offers the 
opportunity to decrease the number of required nanoplatforms during the optimization of the 
nanoplatform for maximal efficacy.  
Run	   Three-­‐factor	  
	  
	   Four	  factor	  
	   	  
	  
x1	   x2	   x3	   	   x1	   x2	   x3	   x4	  
1	   0	   0	   0	   	   0	   0	   0	   0	  
2	   1	   0	   0	   	   1	   0	   0	   0	  
3	   0.5	   0.866	   0	   	   0.5	   0.866	   0	   0	  
4	   0.5	   0.289	   0.817	   	   0	   0.289	   0.817	   0	  
5	   0.5	   0	   0	   	   0	   0.289	   0.204	   0.791	  
6	   -­‐1	   -­‐0.866	   0	   	   -­‐1	   0	   0	   0	  
7	   -­‐0.5	   -­‐0.289	   -­‐0.817	   	   -­‐0.5	   -­‐0.866	   0	   0	  
8	   -­‐0.5	   -­‐0.866	   0	   	   -­‐0.5	   -­‐0.289	   -­‐0.817	   0	  
9	   0.5	   -­‐0.289	   -­‐0.817	   	   -­‐0.5	   -­‐0.289	   -­‐0.204	   -­‐0.791	  
10	   -­‐0.5	   0.866	   0	   	   0.5	   -­‐0.866	   0	   0	  
11	   0	   0.577	   -­‐0.817	   	   0.5	   -­‐0.289	   -­‐0.817	   0	  
12	   -­‐0.5	   0.289	   0.817	   	   0.5	   -­‐0.289	   -­‐0.204	   -­‐0.791	  
13	   0	   -­‐0.577	   0.817	   	   -­‐0.5	   0.866	   0	   0	  
14	  
	   	   	  
	   0	   0.577	   -­‐0.817	   0	  
15	  
	   	   	  
	   0	   0.577	   -­‐0.204	   -­‐0.791	  
16	  
	   	   	  
	   -­‐0.5	   0.289	   0.817	   0	  
17	  
	   	   	  
	   0	   -­‐0.577	   0.817	   0	  
18	  
	   	   	  
	   0	   0	   0.613	   -­‐0.791	  
19	  
	   	   	  
	   -­‐0.5	   0.289	   0.204	   0.791	  
20	  
	   	   	  
	   0	   -­‐0.577	   0.204	   0.791	  
21	  
	   	   	  
	   0	   0	   -­‐0.613	   0.791	  
 
Table 2-3 Doehlert matrix for three and four independent variables1 
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Chapter 3 -  Synthesis and Characterization of a Fe/Fe3O4 Based 
Drug Delivery System  
3.1 Iron Nanoparticles in Drug Delivery 
Particles with a diameter within 1 to 100 nm are considered nanoparticles. With the 
emergence of nanotechnology, tailored nanomaterials have shown a wide variety of applications 
in engineering and biomedical techniques. In modern medicine, applications include both 
diagnosis and treatment of various disease conditions by using them as contrasting agents for 
magnetic imaging, and as drug delivery agents, or as a drug itself.1 Nanoparticles have 
characteristic properties, such as chemical reactivity, energy absorption, and mobility that greatly 
depend on their size.2 Among various types of nanoparticles, metallic nanoparticles, such as gold 
nanoparticles, silver nanoparticles, and iron oxide nanoparticles, are currently showing 
promising results in biomedical applications as diagnostic or therapeutic tools.3,4  
Iron is an abundant metal and has been used since ancient times in many industrial 
applications and as therapeutic agent.5 Therefore, iron has become a potential candidate in 
nanotechnology-based applications of metallic nanoparticles. Iron has three main oxides FeO, 
Fe2O3, and Fe3O4. Bulk Fe2O3 and Fe3O4 are paramagnetic, whereas they are superparamagnetic 
when nanoscopic.6 Due to the characteristic properties of Fe2O3 and Fe3O4, such as magnetism, 
and biocompatibility, they have potential applications as contrast agents in magnetic resonance 
imaging, targeted drug delivery, hyperthermia, gene delivery and early detection of inflammatory 
diseases and cancers.6,7,8 In the area of targeted drug delivery, nanoparticles, and here especially 
the iron oxide nanoparticles, are advantageous due to their high surface areas that can be easily 
modified with chemical ligands. For targeted drug activity in vivo, Fe2O3 is considered one of the 
34 
 
best candidates due to the presence of iron (III) in the nanoparticle core, which is less toxic to 
human body. On the other hand Fe3O4 is considered an excellent contrasting candidate for 
magnetic resonance imaging and hyperthermia.9  
Iron is an essential mineral for biological systems (including humans) due to its activity 
as electron donor and acceptor.  For instance, it is the vital component in hemoglobin and 
required for proper activity of numerous enzymes within the body.10 Therefore, leaching of iron 
form the delivery systems will not cause drastic toxic effects, as ferric/ferrous ions will be either 
stored or excreted from the body by general elimination mechanisms.9 Size plays a major role in 
prolonged blood circulation of nanoparticles due to the uptake of nanoparticles by the 
reticuloendothelial system (RES) in the body. Larger nanoparticles with diameter above 200 nm 
are accumulated within the spleen by mechanical filtration while nanoparticles less than 10 nm 
will be removed from the blood circulation system by renal excretion and extravasation. 
Therefore, nanoparticles with diameters ranging from 10 nm-100 nm feature optimal sizes in 
order to maintain prolonged blood circulation and selective accumulation within the tumor 
compartment for efficient drug delivery mechanisms.11 
3.2 Uptake Mechanisms of Nanoparticles by Cancer Tissues 
Once the nanoparticles are intravenously administered to the blood stream, they are 
selectively delivered to the tumor compartments via passive targeting and active targeting 
mechanisms. In passive targeting mechanisms, nanoparticles with correct dimensions are 
selectively accumulated in the cancer compartments due to enhanced permeability and retention 
effects of the cancerous tissues.12 During tumor propagation, tumor-surrounding areas are highly 
vascularized in order to provide sufficient nutrients and oxygen supply for rapid growth of tumor 
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cells. Therefore, the rapid formation of tumor blood vessels through angiogenesis causes 
deficient blood vessels with leaky irregular endothelial cells compared to normal healthy tissues. 
As a result, the tumor vasculature becomes more permeable for macromolecular transportation 
through the gaps formed between the endothelial cells.13 Properly synthesized nanoparticles with 
correct dimensions have ability to permeate through the endothelial cells and selectively 
accumulate within the tumor environments.   
 
Figure 3.1 Passive targeting of the nanoparticles in cancer cells via enhanced permeable 
retention effects14 
In addition to passive targeting, nanoparticles are also capable of selectively delivering 
their cargo to the tumor periphery via active targeting, as already discussed in chapter 01. Active 
targeting of nanoparticles is achieved by introducing antibodies or targeting ligands onto the 
surface of nanoparticles, which selectively bind to overexpressed receptors present on tumor 
blood cells or tumor vasculature. 
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3.2.1 Tumor Homing Peptides in Tumor Specific Active Targeting 
A short peptide sequence (CGKRK) is used in my nanoparticle based drug delivery 
system as the tumor homing sequence, which is bound to the dopamine ligands present on the 
Fe/Fe3O4 nanoparticles. CGKRK facilitates the active targeting of tumors. The RGD peptide is 
the first tumor targeting peptide that has been discovered.15 To date, RGD is still one of the 
widely used homing sequences. It selectively targets integrin receptors present on the tumor 
cells. Other than the RGD sequence, several other peptides sequences are currently under 
investigations for their homing activity in cancer research, such as CGKRK, NGR, TCP-1, iRGD 
etc.16 
As already discussed, CGKRK has been used in this research as the targeting moiety, due 
to its dual targeting nature, as its targeting receptor heparan sulfate is present on both, 
neovascular endothelial cells and tumor cells. Hoffmann and coworkers reported evidence to 
support this fact when luminol labeled CGKRK was used for studying the uptake mechanism. 
Luminol associated CGKRK is found on the surface of the endothelium cells, as well as in the 
tumor periphery. They further reported that this phenomenon is observed only with CGKRK and 
not with other peptides labeled with the fluorescein dye. Therefore, accumulation of CGKRK on 
tumor vasculature is not due to the EPR effect, but a rather specific targeting mechanisms that is 
followed by this short peptide sequence.17 Other than enhancing cellular uptake of the drugs by 
most tumors, CGKRK also targets the mitochondria and nuclei once it has entered the tumor 
cells. CGKRK is a cationic molecule. Therefore it selectively binds to the anionic phospholipid 
receptors on the cells. CGKRK in bulk quantities is inexpensive and commonly carried out by 
means of solid phase peptide synthesis.  
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3.2.1.1 Solid Phase Peptide Synthesis 
In chemical synthesis, reactions can be carried out in gas, liquid or solid phases. Solid 
phase synthesis has become more prominent in peptide synthesis and DNA synthesis. Generally, 
in solid phase synthesis molecules are bound to a solid support and stepwise reactions are carried 
out in a reactant medium where byproducts or unreacted materials are easily removed by 
washing with suitable solvents.  In peptide synthesis, the peptide chain is synthesized from the C 
terminus to the N terminus by introducing one amino acid at a time via amide bond formation. 
The first amino acid is coupled to a polystyrene resin, which act as the solid support. Functional 
groups of the side chains of the amino acids are protected by protecting groups to avoid coupling 
reactions with upcoming amino acids. Finally, the peptide is cut from the resin to obtain the 
desired sequence. A schematic representation of solid phase synthesis is summarized in Figure 
3.2, as shown below. 
The terminal amine groups of their corresponding amino acids are generally protected 
with Fmoc (9-fluorenylmethyloxycarbonyl) and Boc (t-butyloxycarbonyl) groups that can be 
selectively cleaved by acids or bases.18 The side chain protecting groups are stable under reaction 
conditions, but eventually removed at the final stage to obtain the desired peptide sequence.  
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Figure 3.2 Schematic representation of solid phase peptide synthesis19 
3.3 Synthesis and Surface Functionalization of Fe/Fe3O4 nanoparticles 
Iron nanoparticles can be synthesized by several methods such as thermal decomposition 
of iron pentacarbonyl, sonochemical decomposition of iron carbonyl, reduction of iron 
salts/oxides, and synthesis by vapor phase are well established.20 Successful synthesis of 
monodispersed Fe(0) nanoparticles via thermal decomposition of iron pentacarbonyl (Fe(CO)5) 
is carried out in the Bossmann laboratories. Formation of a thin layer of Fe3O4 around the core 
Fe(0) particles is achieved in-situ by selective oxidation by air with the aid of 
hexadecylammonium chloride.  
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3.3.1 Surface Functionalization of Fe/Fe3O4 Nanoparticles 
Iron nanoparticles are highly sensitive to atmospheric oxygen thereby undergoing further 
oxidation and reduction of the volume of the Fe(0) core. Therefore, a strongly adhesive Fe3O4 
layer is synthesized around the Fe(0) core by air oxidation (see above) to protect the zero-valent 
iron core. The surface of the outer iron oxide layer can be functionalized with various types of 
materials to minimize the biocorrosion when they are used in biological applications. 
 Rajh et al have reported that bidentate ligands, such as dopamine have the ability of 
converting the under-coordinated surface sites of magnetite nanoparticles to a bulk like lattice 
structure with octahedral geometry for oxygen coordinated irons. This lattice formation enhances 
a tight binding of the dopamine to the surface of nanoparticles. Furthermore, a Langmuir 
isotherm of dopamine chemisorption indicates that desorption of dopamine from Fe3O4 surfaces 
is less favorable than adsorption.21,22 Thus, stable interaction between iron and dopamine is 
established, which minimizes the bio corrosion of iron nanoparticles by their surrounding 
aqueous media. In addition to the stabilization of the Fe3O4 surface of the nanoparticles, 
dopamine also provide versatile linkage to couple other ligands or therapeutic components to the 
nanoparticle via amide bond formation reactions with the terminal primary amine of dopamine.  
Finally, the hydrophilic nature of the primary amine group enhances the satisfactory solubility of 
the drug delivery system in physiological media.  
Iron oxide nanoparticles are further functionalized with dopamine-maleimide ligands to 
couple the homing peptide sequence and desired drug onto the nanoparticles. Maleimide is an 
unsaturated imide and important molecule in chemical synthesis due to its reactivity toward 
Diels-Alder reactions and Michael addition reactions. The main purpose of introducing the 
maleimide moiety onto the nanoparticles through dopamine is to couple the homing peptide 
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sequence and doxorubicin via Michael addition reactions.  Dopamine and dopamine maleimides, 
as well as adsorption to nanoparticles are shown in Figure 3.3 below. 
 
Figure 3.3 Iron oxide nanoparticles functionalized with dopamine and dopamine maleimide 
ligands  
3.4 Experiments and Results 
3.4.1 Synthesis of Core/shell Fe/Fe3O4 Nanoparticles 
Fe/Fe3O4 nanoparticles were synthesized by thermal decomposition of Fe(CO)5 in the 
presence of oleylamine and hexadecylammonium chloride (HADxHCl) using 1-octadecene 
(ODE) as solvent originally published in Sun et al.23 This reaction produces Fe(0) atoms, which 
aggregate to form the initial sub-nanometer clusters. The reaction temperature is then lowered to 
180oC. The Fe(0) clusters are capable of catalyzing the thermal decomposition of Fe(CO)5. In the 
presence of the binary ligand system oleylamine/ hexadecylamine x HCl this process leads to the 
controlled growth of iron(0) nanoparticles. Depending on the iron pentacarbonyl concentration, 
initial reaction time and temperature, as well as the duration and temperature of the subsequent 
ripening procedure, near monodisperse (polydispersity < 1.03) nanoparticles possessing 
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diameters between 5 nm and 100 nm can be prepared.24 The second step in nanoparticle synthesis 
consists in the defined oxidation of the surface Fe(0) to Fe3O4. Dr. Hongwang Wang has 
optimized this procedure in the Bossmann group by bubbling O2/N2 mixtures through a 
dispersion of the initially prepared nanoparticles at room temperature. By selecting the duration 
of air oxidation, various chain thicknesses can be achieved. The transmission electron 
microscopy (TEM) images and high-resolution transmission electron microscopy (HRTEM) 
image of the obtained nanoparticles are shown in Figure 3.4. The nanoparticles have a well-
defined core/shell structure, with the average Fe(0) core diameter of 20 ± 0.5 nm and the Fe3O4 
shell thickness of 2.0 ± 0.5 nm, respectively. The TEM characterization revealed that the bulk 
Fe(0) phase is crystalline, but not monocrystalline. Several crystallites are combined in the Fe(0) 
core of each nanoparticle. The outer Fe3O4 layer, is able to protect the Fe(0) core against aqueous 
buffers and under air. However, slow oxidation of the Fe(0) cores is observed in cell experiments 
(see Figure 3.4). 
 
Figure 3.4 (a, b) TEM and (c) HRTEM images of Fe/Fe3O4-core/shell nanoparticles 
 
This synthetic procedure was scaled up to 100g batches in 2013 in the Bossmann group. 
Kansas State University Research Foundation (KSURF) in collaboration with Kansas State 
University’s Institute for Commercialization (KSU-IC) is currently pursuing a combined patent 
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with Battelle Memorial Institute, Columbus, OH. The resulting nanoparticles were further 
characterized by means of XRD and XPS. 
Powder X-ray diffraction (XRD) patterns were obtained on a Bruker D8 X-ray 
diffractometer with Cu Kα radiation.25 The XRD pattern (as shown in Figure 3.5) is indicative of 
the presence of bcc Fe(0) as bulk phase. 
 
Figure 3.5 XRD pattern of the synthesized Fe/Fe3O4 nanoparticles after ligand exchange 
oleylamine/ hexadecylamine x HCl vs. dopamine 
 
X-ray photoelectron spectroscopy (XPS) data26 was recorded with a Perkin–Elmer PHI 
5400 electron spectrometer using acrochromatic Al Kα radiation (1486.6 eV). Analysis was 
carried out under vacuum less than 5 × 10−9 Torr and heated to 120 oC to remove any adsorbed 
molecules on the surface. The XPS binding energies were measured with a precision of 0.025 
eV. The analyzer pass energy was set to 17.9 eV, the contact time was 50 ms, and the area 
scanned was 4 mm2. 
XPS is able to reveal the chemical surface composition of the nanoparticles. Typically, it 
can analyze nanoparticles to a depth of 1-2 nm. Therefore, it is unable to discern the bulk 
composition. The XPS measurements shown in Figure 3.6 were performed by Dr. Myles 
Ikenberry in the group of Prof. Dr. Keith Hohn, Department of Chemical Engineering, Kansas 
State University. Shown is the surface composition after nanoparticle synthesis and after 
exchange of oleylamine/ hexadecylamine x HCl against dopamine. XPS clearly indicates the 
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presence of Fe3O4 at the nanoparticles’ surface, as a comparison with literature findings 
indicates.27 
 
Figure 3.6 Iron, oxygen, nitrogen, carbon and chloride content at the catalyst surface, as 
determined by XPS. a) Freshly synthesized Fe/Fe3O4 nanoparticles (after air oxidation). b) 
Fe/Fe3O4 nanoparticles after ligand exchange with dopamine. 
  
Sample Fe  O  N  C  Cl 
a) Fe/Fe3O4 featuring oleylamine/ 
hexadecylamine x HCl at the surface 
3.5 29.7 2.7 60.6 3.5 
b) Dopamine exchanged Fe/Fe3O4 
nanoparticles 
4.7 33.4 11.1 50.6 0.2 
 
Table 3-1 Iron, oxygen, nitrogen, carbon and chloride content at the catalyst surface, as 
determined by XPS. a) Freshly synthesized Fe/Fe3O4 nanoparticles (after air oxidation). b) 
Fe/Fe3O4 nanoparticles after ligand exchange with dopamine. 
 
In both nanoparticles, the inorganic surface consisted of Fe3O4. The observed increase in 
nitrogen and oxygen content, together with a decrease in carbon and chlorine content at the 
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surface indicates exchange of oleylamine/ hexadecylamine x HCl against dopamine. 
Unfortunately, XPS is only a semiquantitative analysis method. 
3.4.1.1 Determination of Iron Content in the Nanoparticles 
Inductively coupled plasma optical emission spectroscopy (ICP-OES) is used for the 
quantitative measurement of the iron content of the nanoparticles. This is an emission 
spectroscopic technique very specific for a given element, and the intensity of the energy emitted 
at the chosen wavelength is proportional to the amount (concentration) of that element in the 
analyzed sample.28  
A standard series of Fe(II) ranging from 10-50 ppm was prepared from the 1000 ppm ICP 
standard stock solution using 20% HNO3. Dopamine ligand modified Fe/Fe3O4 core/shell 
nanoparticle samples were subjected to ICP studies. The samples were prepared by dissolving 
the nanoparticle samples in conc. HNO3 for 1 hour with constant stirring. Then the samples were 
filtered and diluted with distilled water. The measurements were conducted using the inductively 
coupled plasma optical emission spectrophotometer (Varian 720-ES) at the Department of 
Agronomy. The excitation wavelength was 259.94 nm. The test concentrations were determined 
using the standard curve. 
3.4.2 Functionalization of Core/shell Fe/Fe3O4 Nanoparticles with Dopamine 
Ligands 
3.4.2.1 Synthesis of Dopamine Maleimide Ligands 
Dopamine maleimide ligand synthesis was carried out with modified procedures, 
previously published in Geiseler et al.29 Initially, maleimide was activated by reacting with ethyl 
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chloroformate in the presence of N-methylmorpholine to obtain N-ethoxycarbonylmaleimide. 
This intermediate product was then reacted with dopamine hydrochloride in saturated NaHCO3 
solution in absence of light followed by acid treatment to obtain the final product. The final 
product is further purified by column chromatography and characterized by 1H NMR.  
 
Figure 3.7 Synthesis of the dopamine maleimide ligand  
3.4.2.2 Surface Modification of Nanoparticles with Dopamine Ligands 
The surface of the iron/iron oxide nanoparticles was modified with both dopamine 
hydrochloride and dopamine maleimide ligands. The number of ligands required to form a 
complete monolayer on the nanoparticle surface is calculated assuming a Poisson distribution. 
There were mainly two assumptions taken into consideration during this calculation. We 
assumed that the nanoparticles are perfect spheres and the space demand of one dopamine linker 
is 1.094 x 10-18 m2, as calculated from its Connolly solvent excluded volume of 1.075 x 10-28 
m3.30 This data is available from the program package Chemdraw 3D (Cambridge Soft 
Corporation, 1999). The space demand was calculated by assuming a sphere for dopamine. This 
permitted the calculation the area of the circle with the same diameter than the sphere. 
We further assumed that each ligand has the same affinity towards surface binding so that 
the binding of multiple ligands that form a monolayer at the surface of the nanoparticle can be 
described by a Poisson distribution. 
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Poisson distribution is used to predict the number of events occurring in a specified 
interval such as area and volume, with a known average rate and independently of the time since 
the last event. 
 
Where λ: expected number of occurrences 
k: integer number of occurrences 
f: probability for exactly k occurrences 
As it is shown in the Figure 3.6 the number of dopamine or dopamine-based ligands is 
1150 if the nanoparticle has a diameter of 20 nm. Furthermore, in order to maintain the sufficient 
water solubility of the Fe/Fe3O4 nanoparticles up to 230 maleimide-functionalized dopamines are 
tethered onto the surface of the nanoparticles.  
 
Figure 3.8 Number of dopamines per nanoparticle surface, assuming a dense packing of 
dopamine molecules at a spherical surface.  
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The coating of nanoparticles with dopamine ligands is achieved by reaction of 
nanoparticles and dopamine in chloroform solution. In brief, dopamine and dopamine maleimide 
ligands (4:1 ratio) in chloroform solution was added to Fe/Fe3O4 nanoparticles dispersed in 
chloroform. This dispersion was sonicated for 30 min and shaken on mechanical shaker for 1 
hour. This step was repeated for 6-7 hours. The nanoparticles are collected by centrifugation and 
washed with chloroform for 3 times. Finally, the nanoparticles are dispersed in chloroform until 
further use. The following Figure 3.7 shows the increase of water solubility of the Fe/Fe3O4 
nanoparticles once functionalized with dopamine/dopamine maleimide ligands compared to 
“bare” nanoparticles with no/minimum surface functionalized ligands.	  
 
Figure 3.9 Fe/Fe3O4 solubility before and after with surface functionalization using 
dopamine and dopamine maleimide ligands 
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Characterization of the dopamine bound nanoparticles is carried out by IR spectroscopic 
methods. As shown in Figure 3.8, the IR spectra clearly indicate the surface modifications of the 
iron/iron oxide nanoparticles with dopamine due to the presence of characteristic peaks of the 
dopamine ligands, such as the broad peak at 1644cm-1 due to the aromatic C=C stretching, the 
peak at 1483cm-1 due to C=C bending, and the strong peak at 1263cm-1 due to the C-O stretching 
of the dopamine moiety. 
 
Figure 3.8 IR spectra of “bare” Fe/Fe3O4 nanoparticles and dopamine functionalized 
Fe/Fe3O4 nanoparticles  
  
Iron/iron oxide nanoparticle based drug delivery systems were constructed using the 
dopamine-functionalized nanoparticles and coupling the targeting ligand, the CGKRK peptide 
and doxorubicin as model drug, onto the nanoparticles via dopamine maleimide ligands. A series 
of nanoparticle based drug system was constructed by simply changing the ratio between the 
number of molecules of CGKRK and doxorubicin following the experimental design method as 
explained in chapter 2. Two Doehlert matrices were constructed where one matrix studies the 
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homing activity at five levels and the second matrix studies the doxorubicin effect on 
topoisomerase inhibition at five levels. Following the design of the two matrices, 14 different 
nanoparticle based systems were synthesized. The corresponding Doehlert matrices are tabulated 
in Tables 3.1 and 3.2. 
Run Coded value X1 
Real value X1 Coded value 
X2 
Real value X2 
(No. of CGKRK molecules ) (No. of Doxorubicin molecules) 
1 0 80 0 80 
2 1 128 0 80 
3 0.5 104 0.866 120 
4 -1 32 0 80 
5 -0.5 56 -0.866 40 
6 0.5 104 -0.866 40 
7 -0.5 56 0.866 120 
  
Table 3-2 Doehlert matrix to study the nanoparticle efficacy where it investigates CGKRK 
homing activity at five levels and topoisomerase II inhibitor activity at three levels 
Run Coded value 
X1 
Real value X1 Coded 
value X2 
Real value X2 
(No. of Doxorubicin 
molecules ) 
(No. of CGKRK molecules) 
8 0 80 0 80 
9 1 128 0 80 
10 0.5 104 0.866 120 
11 -1 32 0 80 
12 -0.5 56 -0.866 40 
13 0.5 104 -0.866 40 
14 -0.5 56 0.866 120 
 
Table 3-3 Doehlert matrix to study the nanoparticle efficacy where it investigates 
topoisomerase II inhibitor activity at five levels and CGKRK homing activity at three levels 
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Coupling of CGKRK molecule to the free dopamine ligand was carried out prior to the 
binding of doxorubicin to the nanoplatform to optimize the conditions for the Michael Addition 
at the surface of the nanoparticle. 
3.4.3 Coupling of CGKRK and Doxorubicin to Dopamine Maleimide  
The thiol (-SH) group present in cysteine amino acid of CGKRK selectively reacts with 
the double bond of the maleimide moiety via Michael addition reaction under favorable pH 
conditions (pH 6.5-7.5).31 Dopamine-maleimide and CGKRK were reacted in 1:1 mole ration in 
phosphate saline buffer buffer (PBS) with the pH at 7.0.  The pH value of the medium controls 
the reaction. Consequently, alteration of the pH (to values outside the optimal range) led to poor 
reaction without desired coupling product. The synthetic scheme is given below in Figure 3.9. 
After 24 h of reaction, the mixture was lyophilized and the coupling product was characterized by 
mass spectrometry. This optimized condition (pH=7.0) was used to couple GCKRK to dopamine 
maleimide on the iron/iron oxide nanoparticles. 
 
Figure 3.9 Coupling of CGKRK to dopamine maleimide 
 
The quantitative analysis of CGKRK bound to the dopamine-maleimide ligands on the 
Fe/Fe3O4 nanoparticles was carried out by measuring the sulfur (S) content using ICP-OES 
measurements. The samples prepared for the analysis of iron content were also analyzed for 
sulfur content using a standard series of S(1000 ug/ml S in water, prepared with high purity 
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H2SO4 in water) ranging from 2-10 ppm prepared from the 1000 ppm ICP standard stock 
solution using 20% HNO3. The excitation wavelength was 181.97 nm. The test concentrations 
were then determined using the standard curve. The amount of S present in each sample is 
directly relates to the number of CGKRK molecules attached on to the nanoparticles via thiol 
maleimide double bond formation.  
Primary amines also undergo Michael addition reactions with maleimide double bonds. 
When both thiol and primary amine groups are present, the primary amines add to maleimide in 
competition to thiol groups. This reaction also favors slightly basic conditions, where the pH is 
higher than pH > 7.0.31Therefore, the coupling of hydrophobic doxorubicin to the maleimide 
double bond was also carried out in similar manner in PBS buffer with dopamine-maleimide 
present on the iron/iron oxide nanoparticles. Doxorubicin is commercially available as 
hydrochloride salt to increase its clinical applications. Therefore, hydrophobic doxorubicin with 
free primary amine is obtained via reaction with triethyl amine.  Briefly, two molar equivalents 
of triethyl amine were added to doxorubicin hydrochloride, dissolved in DMF, and the mixture 
was stirred overnight. Hydrophobic doxorubicin was extracted using methylene chloride. Dry 
solid hydrophobic doxorubicin was obtained by evaporating the methylene chloride.  The 
Michael addition reaction between the dopamine-maleimide and the hydrophobic doxorubicin 
was also carried out in phosphate saline buffer medium for 24 hours. 
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Figure 3.10 Structure of Doxorubicin coupled dopamine maleimide  
 
After the reaction nanoparticles were thoroughly washed with 1x PBS solution for four 
times, these washings were analyzed using UV-Vis spectrophotometry to check the presence of 
unbound doxorubicin in the washing solutions. As Figure 3.11 shown below, washing solutions 
did not show the presence of free doxorubicin, as indicated by its missing absorption peak at 480 
nm. Hence, it can be concluded that doxorubicin is coupled to the maleimide moieties on the 
nanoparticles via Michael addition reactions.  
 
Figure 3.11 UV-Vis absorbance spectra of washing solutions of doxorubicin coupled 
iron/iron oxide nanoparticles 
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The doxorubicin-attached iron/iron oxide nanoparticle system was also characterized by 
fluorescence measurements in order to verify the presence of doxorubicin on the nanoparticle. 
The data is shown in Figure 3.12. Doxorubicin fluorescence emission occurs at 560-590 nm. 
Doxorubicin bound nanoparticles showed two emission peaks in the range of 550-600 nm, 
indicating the presence of doxorubicin on the nanoparticle system.   
 
Figure 3.10 Fluorescence emission spectra for free doxorubicin and nanoparticle bound 
doxorubicin in the drug delivery system 
 
The presence of doxorubicin on the iron/iron oxide nanoparticles was further studied by 
HPLC analysis. The standard doxorubicin hydrochloride has a retention time of 5.6 min when 
using a standard reverse phase C18 column and a acetonitrile:water (30:80 v/v) mixture as eluent 
Doxorubicin coupled iron/iron oxide nanoparticles (sample number 17 – 200 doxorubicin 
molecules per nanoparticle) were treated with 10% HCl solution and mechanically shaken for 10 
min. Once all the iron/ron oxide nanoparticles dissolved in the solution and the solution became 
clear, free doxorubicin was extracted into methylene chloride solution. This procedure used 1.00 
mL of CH2Cl2 and 1.00 mL of aqueous HCl-containing solution. It was intensely stirred for 20 
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min. at ambient temperature, prior to separating the organic phase by using a syringe. Methylene 
chloride layer was filtered using 0.25 µm poltcarbonate filters. This solution was directly used 
for the HPLC-analysis. The two chromatograms were shown below (Figure 3.11). 
HPLC data provide evidence for the presence of doxorubicin bound to the nanoparticles 
and the release of the doxorubicin from the nanoparticles at lower pH values (10% HCl in the 
medium). However, this method is not suitable to distinguish between chemisorbed and 
physisorbed doxorubicin, because the Michael addition reaction coupling doxorubicin to 
maleimide is revesible at strongly acidic pH. 
 
Figure3.11 HPLC chromatogram for standard doxorubicin hydrochloride and doxorubicin 
released from the iron/iron oxide nanoparticles treated with 10% HCl 
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3.4.4 Particle Size Evaluation of the Fe/Fe3O4 Nanoparticles Based Drug 
Delivery System 
Dynamic Light scattering (DLS) experiments were carried out to evaluate the effective 
diameters of the iron/iron oxide nanoparticles based drug delivery system, as the size of the 
nanoparticles play an important role in blood circulation and passive uptake mechanisms by 
tumor vasculature. As shown in Figure 3.13, dopamine functionalized Fe/Fe3O4 nanoparticles 
featured an average diameter of 440 nm – 485 nm in deionized water (50 µl of nanoparticle 
solution (1.0 mg ml-1) diluted in 3 ml of deionized water). 
 
Figure 3.12 DLS data for dopamine functionalized Fe/Fe3O4 nanoparticles  
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The polydispersity value ranged from 0.29% - 0.31%, which indicates a low 
polydispersity of the iron/ iron oxide nanoparticles in deionized water medium. Similarly, when 
homing peptide and doxorubicin were coupled to iron / iron oxide nanoparticles, they were also 
of low polydispersity in deionized water, ranging from 0.28% to 0.35%, even though they tend to 
aggregate in the aqueous medium. The effective diameters of the drug-loaded nanoparticles were 
about 450 nm to 500 nm. The DLS results are shown in Figure 3.14. 
 
Figure 3.13 DLS data for drug-loaded dopamine functionalized Fe/Fe3O4 nanoparticles  
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3.5 Conclusions 
Synthesis of iron / iron oxide nanoparticles, which resemble a core/shell Fe/Fe3O4 
structure, was successfully carried out using a thermal decomposition method of iron 
pentacarbonyl. The obtained nanoparticles have a low polydispersity. Their effective diameter is 
about 20 ± 2 nm. Furthermore, the surfaces of the Fe/Fe3O4 nanoparticles were functionalized 
with dopamine and dopamine-maleimide ligands to enhance their water solubility. Then, the 
coupling of theranostic components, which are homing sequences and chemotherapeutic drugs 
(CGKRK and doxorubicin, respectively) was achieved. The double bond of the maleimide 
moiety was used for the coupling of both, CGKRK and doxorubicin, to the iron / iron oxide 
nanoparticles to develop the drug delivery system in accordance with the proposed model based 
on the Ringsdorf model. Thus, a series of iron / iron oxide based nanoparticle systems were 
constructed with different ratios between the homing peptide and topoisomerase inhibitor 
doxorubicin. The therapeutic efficacy of the system was evaluated using pancreatic cancer cell 
lines Pan02 cells. 
3.6 Experimental 
All the chemicals and solutions used in the synthetic procedures were purchased form 
Sigma-Aldrich, Fisher Scientific or Agros International, unless otherwise noted. Characterization 
techniques were carried out using instrumentation available in Kansas State University; Varian 
720-ES ICP-OES spectrophotometer in Department of Agronomy; Shimadzu Prominence LC-
6AD-20A HPLC machine w/ UV/Vis at Department of Grain Science and Industry; 400MHz 
Varian NMR spectrophotometer, Cary 630 FTIR (DR/ATR) spectrophotometer in Department of 
Chemistry; API 2000 LC/MS/MS spectrophotometer (Dr. Duy Hua’s lab), Fluoromax2 
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spectrophotometer (Dr. Daniel Higgins lab) and ZetaPALS zeta potential analyzer are also used 
for the characterization processes.  
3.6.1 Synthesis of the CGKRK Peptide 
CGKRK was synthesized using standard solid phase peptide synthesis methods. 
BrieflyH-Lys(Boc)-Trityl resin was swirled in methylene chloride for 10 min and washed with 
dimethyl formamide. Then, Fmoc protected arginine(R) was added with O-Benzotriazole-
N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate(HBTU) as coupling agent in a mixture of 
diisopropylethylamine (DIEA) and dimethyl formamide (DMF). Fmoc protection of the arginine 
was removed by reaction with 20% piperidine and Fmoc protected lysine(L) was added with a 
mixture of HBTU, DIEA in DMF. These two steps were repeated until the sequence is 
completed. Finally, Fmoc protection of the cysteine was also removed and the CGKRK sequence 
was cleaved from the resin using TFA/TIPS/H2O (90/5/5) solution. The peptide was precipitated 
and washed with cold diethyl ether solution and dried under argon and obtained white precipitate 
as the product. MS-API: m/z 591.5. Molecular weight calculated for 591 
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Figure 3.14 MS –API spectrum of CGKRK peptide sequence 
3.6.2 Synthesis of Fe/Fe3O4 Nanoparticles  
 Iron nanoparticles were prepared by means of a slight modification of a literature 
procedure described by Lacroix et al.23 The apparatus for the synthesis of nanoparticles consisted 
of a 250 mL, three-necked, round-bottom flask utilizing a cold water jacket condenser on the 
middle neck, one septum and one temperature probe on each of the outer necks were attached 
and a spin vane. Then 60 mL 1-octadecene (ODE), 0.9 mL oleylamine and 0.831 g 
hexadecylammonium chloride (HADxHCl) were added into the flask. The reaction system was 
connected to a Schlenk line through the top of the jacket condenser. The reaction mixture was 
degassed at 1200C for 30 min under vigorous stirring. After being refilled with argon, the 
reaction mixture was heated to 1800C. Three portions of 0.7 mL Fe(CO)5 were injected into the 
reaction mixture via syringe, every 20 min. The reaction mixture was kept at 1800C for another 
20 min after the last injection, and then cooled to room temperature naturally. The supernatant 
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was decanted, and the iron nanoparticles accumulated on the magnetic stir bar were washed with 
hexane and ethanol. The product was dried in vacuum and stored in chloroform at 40C under 
argon for further use. 
3.6.2.1 Iron/Iron Oxide Nanoparticle Characterization Using Transmission 
Electron Microscopy (TEM) 
Sample preparation and data collection are similarly described in the literature.32 Briefly, 
samples were prepared by suspending the catalyst in ethanol and agitating in an ultrasonic bath 
for 15 minutes. 10 µL of catalyst sample was placed onto copper mesh grid with lacey carbon 
film. The wet grids were allowed to air-dry for several minutes prior to being examined under 
TEM. The catalyst particle size and morphology were examined by bright-field and dark-field 
transmission electron microscopy (TEM) using an FEI Technai G2 transmission electron 
microscope at an electron acceleration voltage of 200 kV. High resolution images were captured 
using a standardized, normative electron dose and a constant defocus value from the carbon-
coated surfaces.  
3.6.3 Determination of Iron Content in Fe/Fe3O4 Nanoparticles 
A standard curve for the Fe2+ used for the iron quantification using ICP-OES was 
constructed in the range of 10 – 50 ppm solution. The iron content of Fe/Fe3O4 nanoparticles was 
found to be 700mg/L.  
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Figure 3.15 Standard calibration for Fe(II) concentration in ICP-OES measurements 
3.6.4 Synthesis of Dopamine Maleimide Ligands 
 
 
 
 
Synthesis of dopamine maleimide was obtained by a modified procedure of an earlier 
published report by Geiseler et al.29 Initially, maleimide (1.0g, 1.0 eq) was dissolved in ethyl 
acetate (40 ml) in a round bottom flask and the mixture was cooled to 0 oC. N-methyl 
morpholine (1.0 ml, 1.1 eq), dissolved in 5 ml of ethyl acetate, was added drop-wise to the 
mixture during 10min. Then, a solution of ethyl chloroformate (0.932 ml, 1.0eq), dissolved in 2.5 
ml of ethyl acetate, was added drop-wise while keeping the temperature at 0 oC. The mixture was 
warmed to room temperature and stirred for 1 hr. A solid was filtered followed by three 
washings with ethyl acetate. Combined ethyl acetate solutions were washed respectively with sat. 
sodium bicarbonate solution (25 ml x 3), water (20 ml x 2) and brine solution (20 ml). Ethyl 
acetate layer was dried upon anhydrous magnesium sulfate and filtered. Finally, the solvent was 
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evaporated under reduced pressure. The purple product was obtained in 90% yield. 1H NMR 
(CDCl3) δ: 6.65 (s, 2H); 4.33 (q, 2H); 1.33(t, 3H). 
Dopamine maleimide are obtained as followed. In a 125 ml round bottom flask, 
Dopamine hydrochloride (200 mg, 1.0eq) was dissolved in 8 ml of sat. sodium bicarbonate 
solution at 00C in the absence of light. Then N-ethoxycarbonylmaleimide (219 mg, 1.0 eq) was 
added to the mixture and stirred for another 10min at 0 0C, and then brought to room 
temperature. Water (35 ml) was added and further stirred for 40 min, followed by adjusting of 
pH to 1.5 with 30% H2SO4. This solution was extracted with ethyl acetate (25 ml x 4), dried with 
anhydrous magnesium sulfate, filtered, and evaporated under vacuum to obtain the crude 
product. The product was purified by means of silica column chromatography with methylene 
chloride: methanol 10:1 as mobile phase to obtain a pure yellow solid with 65% yield. 1H NMR 
(DMSO-d6) δ: 8.72(s, 1H); 8.61(s, 1H); 6.92(s, 2H); 6.55(d, 1H); 6.49(s, 1H); 6.49(d, 1H); 
3.47(t, 2H); 2.56(t, 2H).   
3.6.5 Coupling of CGKRK and Doxorubicin to Dopamine Maleimide 
 
  
Dopamine maleimide (10 mg, 1.0eq) was dissolved in 2 ml of 1X phosphate saline buffer 
(PBS) with the aid of 1 ml of acetonitrile under argon environment. Then, CGKRK (25mg, 
1.0eq), dissolved in 1 ml of 1X PBS, was added to the mixture and stirred for 24hrs at pH= 7.2 
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under argon.  After 24hr the mixture was lyophilized to obtain a pale yellow solid. MS-API: m/z 
824.6. Calculated molecular weight is 824. 
Doxorubicin hydrochloride (100 mg, 1 eq) and triethyl amine (35 ul, 2.0eq) were mixed 
in dry dimethyl formamide (5 ml) under constant stirring for 12 hrs. Then 5 ml of distilled water 
was added to the medium, mixed properly, and hydrophobic doxorubicin was extracted with 
methylene chloride (3 x 25 ml). The methylene chloride layer was dried with anhydrous MgSO4 
and concentrated in vacuum to yield a dark red solid with a yield of 80%. The obtained 
hydrophobic doxorubicin was also coupled to dopamine maleimide following the same 
procedure as mentioned above for CGKRK. MS-API: m/z fragments observed at 412.9; 251.4; 
379.1, molecular weight calculated for is 776.7. 
3.6.6 Coupling of CGKRK and Doxorubicin to Dopamine Maleimide on 
Iron/Iron Oxide Nanoparticles 
Sample number 1: 
Initially dopamine and dopamine maleimide coated Fe/Fe3O4 nanoparticles 25 mg was 
dispersed in 1 ml solution of 1x PBS buffer was sonicated for 15 min. Then 110 µl of CGKRK 
solution (1 mg in 1 ml of 1x PBS) was added to the nanoparticle mixture. Further sonicated for 5 
min. After that vial containing the mixture was mechanically stirred for 24 h. on a mechanical 
shaker. Then Fe/Fe3O4 nanoparticles were collected by centrifugation at 10000 rpm for 5 min. 
Nanoparticles were washed with 1x PBS solution for three times. Collected nanoparticles were 
dispersed again in 1 ml of 1x PBS solution and sonicated for 10 min. Then 109 µl of doxorubicin 
solution (1 mg in 1 ml of 1x PBS) was added to the nanoparticle solution and stirred for 24 h. on 
a mechanical shaker. Nanoparticles were washed with 1x PBS solution for three times and dried 
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under Argon. Finally recovered Fe/Fe3O4 sample (20 mg) was stored at 4 0C until further use. 
Similar procedure was carried out to synthesize all the other samples as well. 
3.6.7 Determination of Loaded CGKRK Content on to The Iron/Iron Oxide 
Nanoparticles 
A standard curve for the Fe2+ used for the iron quantification using ICP-OES was 
constructed in the range of 2-10 ppm solution. The average amount of CGKRK present on each 
nanoparticle sample is about 400ng/mg. 
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Chapter 4 -  In-Vitro Evaluation of the Nanoparticle-Based 
Nanoplatforms for Treating Pancreatic Cancer 
4.1 Introduction 
Iron/iron oxide nanoparticle based drug delivery systems, constructed according to the 
Ringsdorf model, were tested on murine pancreatic cancer cell lines (Pan02) and on 
noncancerous mouse fibroblast cells (STO), to determine the therapeutic activity of the system 
in-vitro. Preliminary studies of the cellular uptake and cytotoxic effects of the different 
nanoparticle based nanoplatforms in dependence on the ratio between CGKRK and doxorubicin 
were evaluated using cell-based assays. As mentioned previously, CGKRK enhances the cellular 
uptake of the nanoparticle-based systems by binding to the phospholipid heparin sulfate receptor. 
Once the cells take up the nanoparticles, they will selectively accumulated in the lysosomal/early 
endosomal compartments1, which ultimately causes release of the topoisomerase II inhibitor 
doxorubicin. Once released, doxorubicin is transported to the nucleus. 
 
Figure 4.1 Cellular uptake mechanism and fate of the nanoparticle based drug delivery 
system1 
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As shown in Figure 4.1, the targeting ligand CGKRK selectively binds to the receptors 
present on the cell membrane and enhances the cellular uptake of the iron oxide based 
nanoplatform into the pancreatic cancer cells by means of endocytosis. Once the late endosome 
is formed by fusion of the early endosome and the lysosome, the environment inside the 
lysosomal/endosome compartments becomes acidic (pH < 5). This acidic environment is 
responsible for the release of the active drug doxorubicin from the nanoparticles. Doxorubicin 
escapes from the lysosomal membranes and selectively migrates to the nucleus, where it is 
accumulated. While doxorubicin is inside the nucleus, it inhibits DNA replication by 
intercalating into double stranded DNA, which renders topoisomerase II inactive. This induces 
apoptosis of the cells. Furthermore, a fraction of the iron oxide nanoparticle based drug escapes 
the endosome and will be transported to the mitochondria due to the CGKRK activity, which is 
known to facilitate transport to this location. 
4.2 Experiments and Results 
I have carried out the cell-based assays in Dr. Deryl Troyer’s lab in the Department of 
Anatomy and Physiology, College of Veterinary Medicine, Kansas State University.  
4.2.1 Analysis of Cellular Uptake of the Fe/Fe3O4 Nanoparticle Based Drug 
Delivery System 
The cellular uptake levels of the nanoscopic drug delivery system were analyzed by 
employing the Prussian Blue staining method. It is a well-known staining procedure used for the 
qualitative determination of the presence of ferric ions in the cells.2 The Prussian blue reaction 
involves the treatment of cells with ferrocyanide along with hydrochloride acid. Any ferric ion 
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(III) present in the cells reacts with the ferrocyanide and results in the formation of a bright blue 
pigment called Prussian blue, or ferric ferrocyanide.3  
The iron content of the Fe/Fe3O4 nanoparticles was determined to be 700 mg/L by means 
of ICP-AES measurements. Therefore, the concentrations of the drug systems were varied 
depending on the total iron concentrations on the solutions. For the cellular uptake mechanisms, 
low iron concentrations of 5 µg/ml and 10 µg/ml were used. Four different drug formulations 
with different CGKRK to doxorubicin were used for the cellular uptake studies using Pan02 
cells. The loading efficiencies of the nanoparticle-based systems were evaluated using Perl’s 
Prussian Blue stain kit (Polysciences, Inc., Warrington, PA). Pan02 cells plated on 24 well cell 
plates were incubated over night at 370C in humidified containing 5% CO2 with nanoparticles 
solutions in RPMI 1640 with 10% fetal bovine serum (FBS) 1% Penicillin-Streptomycin 
(Penstrap) and 10% 70 kDa dextran. Then, cells were fixed with 10% Neutral Buffered Formalin 
and incubated for 15min. Wells were washed thoroughly with 1 X PBS buffer and stained with 
an aqueous solution of 4% potassium ferrocyanide and 4% hydrochloric acid for 10min. again 
excess staining solutions were washed away with distilled water. Counter staining of the cells 
were carried out using nuclear fast red for 2-5 min. Finally excess counter stain solutions were 
also washed away with 1xPBS solutions. Cells were examined under light microscope with 40X 
magnification. Pan02 cells before and after staining are shown in Figure 4.2 and Figure 4.3. 
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Figure 4.2 a) Pan02 cells incubated in RPMI medium for 24 h; b) Pan02 cells with 10 µg/ml 
iron oxide nanoparticles at 0 h; c) Pan02 cells incubated with iron oxide nanoparticles at 
370C in humidified containing 5% CO2 for 24 h; under light microscope with 40X 
magnification  
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Figure 4.3 Pan02 cells after Prussian Blue staining procedures under light microscope with 
40X magnification a) Control Pan02 cells; b) Pan02 cells incubated with 5 µg/ml of iron 
oxide nanoparticles; c) Pan02 cells incubated with 10 µg/ml of iron oxide nanoparticles 
 
As shown in Figure 4.3, Pan02 cells incubated with iron/iron oxide nanoparticles show 
presence of blue pigments within the cytoplasm of the cells and selectively accumulated around 
the nucleus. In both 5 µg/ml and 10 µg/ml concentrations of iron/iron oxide nanoparticles are 
shown that nanoparticles are selectively taken up by the Pan02 cells, compared to the control 
sample. This provide evidences to support that the iron oxide nanoparticle based drug delivery 
system is biocompatible and taken up by the cancer cell lines.  
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4.2.2 Anti-Proliferating (Cytotoxic) Activity of the Fe/Fe3O4 Nanoparticle 
Based Drug Delivery System 
The colorimetric MTT assay is used in the preliminary in-vitro cytotoxic assays to 
evaluate the toxicity effects of the iron/iron oxide nanoparticle based drug system on Pan02 cells. 
The basic principle of the assay is the reduction of the yellow dye MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) to its insoluble purple formazan form by the 
enzymes presence in mitochondria of living cells. Then this insoluble dye is solubilized using a 
solubilizing buffer and the absorbance of this colored solution is quantified by measuring at a 
certain wavelength (usually 550 nm) by a UV-VIS spectrophotometer, depending on the solution 
medium used for cell growth.4 Formation of the formazan is proportional to the amount of viable 
cells as mitochondrial enzyme activity is responsible of reduction of MTT. 
 
Figure 4.4 Conversion of MTT to formazan dye by mitochondrial reductase enzymes 
 
Three different concentration values (10 µg/ml, 50 µg/ml and 100 µg/ml with respect to 
iron) were prepared from each iron/iron oxide nanoparticle based drug delivery systems along 
with the dopamine/dopamine maleimide coated iron/iron oxide nanoparticles. All the samples 
were tested upon murine pancreatic cancer cells (Pan02) and mouse fibroblast cells (STO) as 
control cells. Mouse fibroblast cells are non-cancerous and therefore used for comparison 
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purposes. The main purpose of the cytotoxicity assays are to evaluate the therapeutic efficacy of 
the drug delivery system and to determine effective ratio between the homing sequence CGKRK 
and topoisomerase II inhibitory doxorubicin content in each nanoparticle system. The sample 
numbers and their corresponding compositions are listed below in table 4.1 for easy 
identification. The samples were constructed using experimental method “Doehlert design” as 
explained in the chapter 03.  
Sample number No. of CGKRK molecules No. of Doxorubicin molecules 
1 80 80 
2 128 80 
3 104 120 
4 32 80 
5 56 40 
6 104 40 
7 56 120 
8 80 80 
9 80 128 
10 120 104 
11 80 32 
12 40 56 
13 40 104 
14 120 56 
D 
 
 
- - 
 Table 4-1 Iron oxide nanoparticle based drug system with corresponding sample number 
for preliminary tests  
Dopamine/dopamine maleimide coated iron oxide nanoparticles, doxorubicin drug itself 
and cells incubated in the growth media were used as controls to evaluate the drug delivery 
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system efficacy with respect to each other. The MTT assay protocol is briefly described in the 
next paragraph. 
Originally, Pan02 cells were cultured in 96 well plates at a concentration of 12500 cell 
per square centimeter in RPMI 1640 medium with 10% FBS and 1% penstrap and incubated at 
370C in humidified air containing 5% CO2 overnight. Growth medium was removed from the 
cell suspensions and iron oxide nanoparticle samples prepared from growth medium are 
introduced to the cells as shown in Figure 4.5.  
 
Figure 4.5 Iron oxide nanoparticle addition layout on the 96 well plates 
 
For each sample a negative control was carried out incubating the cells without any iron/ 
iron oxide nanoparticles and it is denoted as 0 µg/ml. Similarly, 8 plates were used to carry out 
the toxicity assays for all the samples mentioned in the table 4-1. Once the nanoparticles are 
introduced to the cells plates were incubated at 370C in humidified air containing 5% CO2 for 24 
hours. MTT solution was added to the wells in 5-8 columns and incubated again for 4 hours. 
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Insoluble purple formazan pigments were solubilized using solubilizing buffer and same 
procedure was carried out after 48 h for the wells in column 9-12. After 72 hours with initial cell 
incubation on the plates color development was measured at 560 nm and 690 nm using the UV-
Vis spectrophotometry. Absorbance of purple formazan dye is measured at 560 nm and 
absorbance of MTT solution is measured at 690 nm. The schematic representation of the assay 
procedure is shown in figure 4.6. 
 
Figure 4.6 Schematic representation of the MTT assay procedure 
 
As shown in Figure 4.5 each concentration of the sample is quadruplicate. Therefore the 
viability of the cells depending on the iron nanoparticle concentrations was calculated using the 
equation below.  
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𝑐𝑒𝑙𝑙  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦   % = 𝑎 − 𝑏𝑐 − 𝑑   𝑋  100% 
where, 𝑎 is the mean of sample absorbance (Abs560 – Abs690) 
 𝑏 is the mean of MTT assay control absorbance for sample (Abs560 – Abs690) 
 𝑐 is the mean of negative control absorbance (Abs560 – Abs690) 
 𝑑 is the mean of MTT assay control absorbance for negative control (Abs560 – Abs690) 
 
The cell viability of Pan02 cells as a function of the nanodelivery systems used after 24 h 
and 48 h incubation are shown in the graphs below (Figure 4.7).  It is clearly visible that the cell 
viability is over 80% for most of the samples in all three concentrations. When the cells were 
examined under the light microscope it is further evident that the nanoparticles were aggregated 
together in the media and the cell uptake of the nanoparticles are considerably low where there 
were only small fractions of cells with nanoparticle accumulated in the cytoplasm. 
 
Figure 4.7 Percentage cell viability of Pan02 cells with various iron oxide nanoparticle 
systems after 24 and 48 hours 
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In order to minimize the nanoparticle aggregation, dextran has been used successfully in 
the Bossmann laboratories in the project carried out for the early detection of cancers using iron / 
iron oxide based nanoparticle systems. Therefore, the same strategy was used in the in-vitro 
cytotoxic assay measurements, where 10 mg of Dextran (70 kDa) is used for each 1 ml of growth 
medium when preparing the concentration series for the iron/ iron oxide nanoparticles. The MTT 
assay was repeated again, and the percentages for the cell viabilities are shown in Figure 4.8. 
 
Figure 4.8 Percentage cell viabilities of the Pan02 cells after 24 and 48 hours with iron 
oxide nanoparticle systems 
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As shown in Figure 4.8, the percentages of the cell viabilities of the Pan02 cells were 
considerably low compared to the cell viabilities shown in Figure 4.7. This clearly indicated that 
the dextran reduces the aggregation of iron / iron oxide nanoparticles in the growth medium. As 
a result, nanoparticles uptake and cytotoxic activity of the drug system were elevated, which 
ultimately reduced the cell viability of the cancerous Pan02 cells due to the presence of a 
dispersed drug delivery system. Moreover, it clearly indicates that with increasing concentration 
of the iron / iron oxide nanoparticles the cell viability decreases in all the samples. Most notably, 
it shows very high toxicity in samples number 3, 8, 13 and 14 in both 24 hours and 48 hours. 
Since the iron / iron oxide nanoparticle based drug systems comprise of different ratios of 
CGKRK to doxorubicin, a simple correlation of the cell viability with respect to the homing 
ability of CGKRK or doxorubicin does not yield a straightforward result. Therefore, we have to 
assume that a synergistic effect causes the observed cytotoxic activity inside the pancreatic 
tumor cells. In order to evaluate this synergistic effect of the cytotoxicity data and to arrive at the 
best ratio of the two components, a response surface has been drawn with the use of statistical 
analysis method mentioned in the chapter 02. The consequences of its shape will be discussed 
further in chapter 05.  
The MTT assays for all the iron oxide based systems were also carried out on 
noncancerous mouse fibroblast cells (STO) in a similar manner for the comparison of the toxicity 
with respect to the nanoparticle based drug systems on healthy cells. Mouse fibroblast cells were 
cultured in Dulbecco’s Eagle Medium (DMEM) with 10% FBS, 1% penstrap. Iron / iron oxide 
nanoparticle samples were prepared using the same growth medium and dextran (10%) was also 
introduced to the medium. The results for the cell viabilities  (again in percentages) are 
summarized in Figure 4.9. 
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Figure 4.9 Percentage cell viabilities of the STO cells after 24 and 48 hours with iron oxide 
nanoparticle systems 
 
The percentage cell viabilities of the STO cells are ranging between 60% to 100% in all 
of the samples. Among them most compositions of Fe/Fe3O4 nanoparticles, CGKRK and 
doxorubicin show more than 80% viability, except samples 2, 7, 11 and 13. In most of the 
samples, the highest toxicity values were observed for the lowest nanodelivery platform 
concentrations (10ug/ml), which is not a common feature observed in MTT cell viability assays. 
Interestingly, the iron / iron oxide drug delivery systems 3, 8 and 14 ( (104,120), (80, 80) and 
(120, 56) respectively) that showed the highest toxicity on Pan02 cells, did not show significant 
cytotoxicity effects on STO cells at all tested concentrations. However, drug delivery system 
number 13 (40,104) shows about 60% cytotoxicity effects whereas the cytotoxicity values for 
Pan02 cells was about 40%. Based on these results, our studies showed that the iron / iron oxide 
nanoparticle based drug delivery system has potential as anticancer agent in the treatment of 
pancreatic cancers, because compositions can be chosen that are more toxic to cancer cells than 
to healthy cells. 
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The MTT assay has also been carried out using free doxorubicin with Pan02 cells to 
evaluate the cytotoxicity capacity with the same concentrations that were incorporated into the 
iron / iron oxide nanoparticles during the design of the drug delivery system. Depending on the 
number of doxorubicin molecules introduced into the nanoparticle systems, the average number 
of doxorubicin molecules was calculated. The corresponding concentrations for doxorubicin 
were 1 µg/ml, 0.5 and 0.1 µg/ml, for iron oxide nanoparticle concentrations of 100 µg/ml, 50 
µg/ml and 10 µg/ml respectively.  The percentage cell viabilities are shown in Figure 4.10 below. 
 
  Figure 4.10 Percentage cell viabilities of the Pan02 cells incubated with free doxorubicin 
after 24 and 48 hours 
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CGKRK and doxorubicin. There could be also an added cytotoxic effect due to the presence of 
iron. 
4.1.1 Anti-Proliferating (Cytotoxic) Activity of the Fe/Fe3O4 Nanoparticle 
Based Drug Delivery System for Extended Doehlert Matrices 
From the preliminary data obtained by means of Prussian blue staining and MTT assays, 
it can be concluded that the constructed systems show potential as anticancer drug delivery 
agents in treating pancreatic cancers. The Prussian blue staining method shows satisfactory 
nanoparticle uptake by the Pan02 cells, while the MTT assay data show low cell viabilities of 
Pan02 cells, compared to higher cell viabilities of the non-cancerous STO cells. This is 
especially valid in samples number 3, 8 and 14. When looking into the nanoparticle compositions 
that showed higher cytotoxicity activity, we have observed that samples with higher amount of 
doxorubicin showed higher cytotoxicity activity towards Pan02 cells. Therefore, in order to 
further evaluate a potential synergistic effect of CGKRK and doxorubicin on nanoparticles 
towards cell cytotoxicity of Pan02 cells, two additional Doehlert matrices were constructed. As 
described in the chapter 02, the space filling ability of the Doehlert designs was taken into 
consideration when constructing the new matrices. This is clearly an added advantage that 
reduces the experimental time and cost when expanding the cytotoxicity studies in order to find 
the optimal conditions of the nanoparticle system as anticancer therapeutic agent. Iron/iron oxide 
nanoparticles with higher cytotoxicity effects that were obtained from original matrices were 
incorporated in the new matrices with additional iron/iron oxide nanoparticle samples with high 
numbers of CGKRK and doxorubicin molecules.  
In order to synthesize the new nanoparticle systems (15-22), the total number of 
dopamine maleimides on the nanoparticles was increased. Consequently, the new dopamine to 
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dopamine maleimide ratio is set to 1:3, as opposed to the previous 1:4 ratio. Coupling of 
CGKRK and doxorubicin onto the nanoparticles was carried out in a similar manner as 
mentioned in the section 3.4.3 in 1X PBS buffer medium. CGKRK and doxorubicin loaded 
iron/iron oxide nanoparticles were dried and stored at 40 C until further use.  
Corresponding new matrices are tabulated in Tables 4.2 and 4.3.  Samples from the initial 
matrices are denoted in purple columns.  
Run Coded value X1 
Real value X1 Coded value 
X2 
Real value X2 
(No. of CGKRK molecules ) (No. of Doxorubicin molecules) 
3 0 104 0 120 
22 1 152 0 120 
21 0.5 128 0.866 160 
7 -1 56 0 120 
1 -0.5 80 -0.866 80 
2 0.5 128 -0.866 80 
20 -0.5 80 0.866 160 
 
Table 4-2 New Doehlert matrix to evaluate the nanoparticle efficacy studying 
topoisomerase II inhibitor activity at five levels and CGKRK homing activity at three levels 
 
Run Coded value X1 
Real value X1 Coded value 
X2 
Real value X2 
(No. of Doxorubicin molecules ) (No. of CGKRK molecules) 
15 0 152 0 120 
17 1 200 0 120 
18 0.5 176 0.866 160 
10 -1 104 0 120 
9 -0.5 128 -0.866 80 
16 0.5 176 -0.866 80 
19 -0.5 128 0.866 160 
 
Table 4-3 New Doehlert matrix to evaluate the nanoparticle efficacy studying 
topoisomerase II inhibitor activity at five levels and CGKRK homing activity at three levels 
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Spatial arrangements of the new nanoparticle samples with respect to the original samples 
are shown in Figure 4.10 and Figure 4.11. 
 
Figure 4.11 Spatial arrangement of the 2nd Doehlert matrix with respects to initial matrix, 
which studied CGKRK in five levels  
 
 
Figure 4.12 Spatial arrangement of the 2nd Doehlert matrix with respect to the initial 
matrix, which studied Doxorubicin in five levels 
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Antiproliferation assays using newly synthesized nanoparticle systems (15-22) against 
both Pan02 cells and STO cells (control assays) were carried out following the same procedures 
as described in section 4.2.2. It was found in our initial study that the 48 hours cell cytotoxicity 
assays are not statistically significant for any concentrations. Therefore, only the 24 hours cell 
cytotoxicity assays were conducted for the new samples. Cell cytotoxicity data for Pan02 cells 
with respect to all concentrations of each sample are shown in the graphs below. (Figure 4.13). 
 
 
Figure 4.13 Percentage cell viabilities of the Pan02 cells after 24 hours incubation with iron 
/ iron oxide nanoparticle systems 
 
According to Figure 4.13 it is clearly evident that the cell cytotoxicity is further reduced 
when a high doxorubicin content is present on the nanoparticle samples (15-22), compared to the 
previous samples (1-14). Most of the samples show linear correlation with the nanoparticle 
concentration where the percentage cell viability decreases with the increase of concentration.  
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According to the preliminary statistical analysis, the percentage cell viability was not affected by 
the number of CGKRK molecules present on each nanoparticle system (the CGKRK parameters 
were statistically not significant in the chosen model). Assuming that this is still valid for the 
new iron/iron oxide nanoparticle systems, an interesting correlation between the percentage cell 
viability and number of doxorubicin can be derived from the data. It shows the reduction of 
percentage cell viability of the Pan02 cells with increasing number doxorubicin molecules until a 
certain number of doxorubicin molecules is reached. If the concentration of doxorubicin on the 
nanoparticle is further increased, the observed cell viability starts to increase back (showing a 
negative effect on cell cytotoxicity). For example, samples 16, 18 (176 doxorubicin molecules 
per nanoparticle) and sample 17 (200 doxorubicin molecules per nanoparticle) show lower 
cytotoxicity effects than sample 20 and 21 (160 doxorubicin molecules per nanoparticle), which 
show the highest cytotoxicity values. It is interesting that the samples 16 and 18, which have the 
same number of doxorubicin molecules at the nanoparticles’ surface (176), show different 
cytotoxicity effects towards Pan02 cells. This behavior may be due to the difference in the 
number of CGKRK molecules present on each nanoparticle (80 molecules in sample 16 and 160 
in sample 18). Based on the data, prediction of simple correlation between the cell cytotoxicity 
and nanoparticle composition is quite ineffective; therefore a refined statistical analysis of the 
data using response surface methodology was carried out to evaluate potential synergistic effect 
of both CGKRK and doxorubicin against Pan02 cells. To minimize the error term associated 
with the mathematical model, cell cytotoxicity assays for the central point of each Doehlert 
matrices were carried out in triplicates, as described on page 22 chapter 02. 
Comparison of the cell cytotoxicity data of iron/iron oxide nanoparticles for each 
concentration in both Pan02 cells and STO cells are summarized in the Figure 4.14. 
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Figure 4.14 Percentage cell viability comparison of Pan02 cells and STO cells treated with 
iron/iron oxide nanoparticle systems for 10 µg/ml, 50 µg/ml and 100 µg/ml respectively 
 
Among the group of 10 µg/ml concentrations, samples 16 and 17 showed higher toxicity 
towards noncancerous STO cells compared to cancerous Pan02 cells. Cell toxicity of sample 17 
is the highest. This behavior is attributed to the high doxorubicin content on the samples, which 
is highly toxic to the normal STO cells. All the other samples show lower toxicity towards STO 
cells than Pan02 cells, especially samples 20 and 21, which showed higher toxicity effects on 
Pan02 cells. Similar trends are observed at the concentrations of 50 µg/ml and 100 µg/ml for all 
the samples, except sample 17 that showed higher toxicity towards STO cells Pan02 cells at 50 
µg/ml concentration.   Based on these data it is clear that the secondary data obtained from the 
cytotoxicity assays are compatible with the preliminary data. This iron/iron oxide nanoparticle 
based system showed promising results in establishing a novel nanoformulation with potential in 
0	  
20	  
40	  
60	  
80	  
100	  
120	  
140	  
160	  
15	   16	   17	   18	   19	   20	   21	   22	  
ce
ll	  
vi
ab
ili
ty
	  %
	  
sample	  name	  
100ug/ml	   Pan02	  
STO	  
89 
 
the treatment of pancreatic cancer. However, in order to determine whether the activity is based 
on doxorubicin itself or due to the synergistic effect of both CGKRK and doxorubicin, a detailed 
statistical analysis using RSM method was carried out. The RSM methodology and the results of 
the statistical analysis and will be discussed in the next chapter. 
4.2 Conclusion 
In conclusion, the iron / iron oxide nanoparticle based drug delivery system that was 
designed in accordance with the Ringsdorf model, has been successfully used in in-vitro cell-
based assays to determine the cytotoxicity on the murine pancreatic cancer cell line Pan02 and 
on noncancerous mouse fibroblast cells (STO). The cytotoxicity data reported here was further 
studied using by using response surface methodology for determining the best ratio between the 
homing activity and the topoisomerase inhibitory activity. A detailed discussion of the statistical 
analysis will be provided in the next chapter. Even from only preliminary MTT data, it can be 
concluded that the nanoparticle based system shows potential toxicity effects on Pan02 cells, 
while showing minimum cytotoxicity to healthy STO cells. This data gives a clear indication that 
constructing a nanoplatform for drug delivery based on Doehlert methodology has potential.  
Response surface methodology allowed the development of targeted drug delivery in the 
treatment of pancreatic cancers using a nanoparticle as drug carrier. Iron/ iron oxide 
nanoparticles have great potential as universal delivery system capable of treating many cancers 
by changing the targeting moiety or/and drug. 
Therefore, this system will be further developed in the Bossmann group. Potential 
improvements comprise the use of better targeting peptides and the simultaneous use of more 
than one drug to minimize side effects towards non-cancerous cells. Forty years after it has been 
proposed, the Ringsdorf paradigm is still very alive, as this data indicates. 
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4.3 Experimental 
All the experiments were carried out in Dr. Deryl L. Troyer’s lab at Department of 
Veterinary Medicine. Murine pancreatic cancer cell lines (Pan02) and mouse fibroblast cells 
(STO) were cultured in the Troyer laboratories for assay purposes. All the chemicals and 
solutions used in the assay procedures were obtained from the Dr. Troyer’s lab.  
4.3.1 Iron / Iron Oxide Nanoparticle Solution Preparation  
Initially, 1.0 mg of iron/ iron oxide nanoparticles from each sample (14 drug delivery 
systems and dopamine coated nanoparticles) were measured and dissolved in 700 ul of 
appropriate medium (RPMI 1640 for Pan02 cells and DIEM for STO cells) containing 10% FBS, 
1% Penstrap and 10% dextran. The solutions were sonicated for 10 min until the nanoparticles 
dissolved in the solution. The original concentration of each sample is 1.0 mg/ml with respect to 
iron in the nanoparticle system. Then, a dilution series was carried out to prepare 100 µg/ml, 50 
µg/ml and 10 µg/ml as assay sample solutions by diluting the stock solution with the same 
media. For each concentration 1.0 ml was prepared. 
4.3.2 Prussian Blue Staining Procedure 
Pan02 cells plated on 24 well cell plates were incubated overnight at 370C in humidified 
air containing 5% CO2 with 500 ul of nanoparticles solutions with concentration of 10 µg/ml and 
5 µg/ml. Then, cells were fixed with 500 ul of 10% Neutral Buffered Formalin and incubated for 
15min. Wells were washed thoroughly with 1 X PBS buffer and stained with 300ul of an 
aqueous solution of 4% potassium ferrocyanide and 4% hydrochloric acid for 10min. Again, 
excess staining solutions were washed away with distilled water. Counter staining of the cells 
was carried out using 250 ul of nuclear fast red for 2-5 min. Finally, excess counter stain 
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solutions were also washed away with 1xPBS solutions. Cells were examined under a light 
microscope with 40X magnification. 
4.3.3 MTT Assay Procedure 
Pan02 cells were cultured in 96 well plates at a concentration of 12500 cells per square 
centimeter in RPMI 1640 medium with 10% FBS and 1% penstrap and incubated at 370C in 
humidified air containing 5% CO2 overnight. The growth medium was removed from the cell 
suspensions and 75 ul of iron / iron oxide nanoparticle samples prepared were introduced to the 
cells and incubated for 24 h under same incubation conditions. After the 24 h 7.5 ul of MTT 
solution were added to the cells in rows number 5-8 and 75 ul of solubilizing buffer were added 
to the same cells after 4 h of incubation. Likewise, the same procedure was carried out for rows 
number 9-12 after 48 h. Both, cell groups were treated with 75 ul of solubilizing agents after 4 h 
of incubation. Then, the plates were incubated for another 24 h and absorbance measurements 
were carried out using UV-VIS spectrophotometric plate reader in College of Anatomy and 
Physiology.  
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Chapter 5 -  Statistical Analysis of Cytotoxicity Measurements of the 
Nanoparticle Based Drug Delivery System  
As mentioned in chapter 02, a statistical analysis was carried out for the evaluation of 
optimized parameters of the nanoparticle based drug delivery system. The main objective is to 
find out the optimal values for the ratio between the two therapeutic components CGKRK and 
doxorubicin, which are both co-attached on the surface of the Fe/Fe3O4 nanoparticles. In order to 
determine whether the chosen concentrations of iron/ iron oxide nanoparticles and drug ratios 
represent the optimization conditions, the cytotoxicity data was analyzed using statistical 
analysis (Response surface methodology). The statistical evaluation was carried out in three 
main steps, following the methodology description given in section 2.1.  
The two main independent variables (factors) in the system are the number of CGKRK 
molecules and the number of doxorubicin molecules per nanoparticle. Their levels are chosen 
depending on the required solubility parameters of the nanoparticle systems. The lower and 
upper levels of the independent variables (factors) are mentioned in table 3.1 and 3.2 in chapter 
03. These values are mainly depending on the chosen experimental design, which is Doehlert 
design in our case. Doehlert design has been selected due to its advantages over the other 
experimental design methods, as described in section 2.2. Since two independent variables are 
used, the response of the system (percentage cell viability) represents a curvature. Therefore, a 
quadratic response model is constructed to evaluate the data. Finally, verification of the model 
equation was carried out to determine the statistical significance of the model, hence to 
determine the fitness of the chosen mathematical model with respect to the experimental data. 
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5.1 Statistical Analysis Results 
The experimental data was processed using the software STATISTICAL ANAYSIS 
SOFTWARE (SAS®). Statistical analysis was carried out using SAS proc reg and proc rsreg 
methods. Response surfaces were constructed using RSREG methods.  
5.1.1 Analysis of Preliminary Cytotoxicity Data  
 Percentage cell viability (%) 
Sample 
number 
24 hrs 
Sample 
number 
48hrs hrs 
Concentration in µg/ml Concentration in µg/ml 
10 50 100 10 50 100 
1 100 98 88 1 118 109 106 
2 89 94 78 2 81 74 70 
3 74 71 66 3 60 61 52 
4 94 92 81 4 107 108 100 
5 102 96 67 5 119 126 75 
6 91 89 80 6 116 108 107 
7 115 103 71 7 129 124 97 
        
8 80 81 58 8 81 75 55 
9 94 86 69 9 139 115 76 
10 78 75 76 10 87 80 77 
11 88 90 79 11 105 114 75 
12 116 98 81 12 101 85 68 
13 49 56 55 13 53 46 41 
14 90 95 43 14 83 51 42 
 
Table 5-1 Cell cytotoxicity data for two Doehlert matrices depending on the concentration 
and incubation time 
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Six different analyses were carried out, depending on the concentration and incubation 
time for the experimental data, as summarized in Table 5.1. In all the calculations both, first and 
second Doehlert matrices were combined to obtain the required replications. Initially, a full 
quadratic response surface model with both CGKRK and doxorubicin was constructed and 
analyzed, with the intent to determine the presence of any outliers.   
 𝑐𝑒𝑙𝑙  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝛽! + 𝛽!𝐷𝑜𝑥 + 𝛽!𝐷𝑜𝑥! + 𝛽!𝐶𝐺𝐾𝑅𝐾 + 𝛽!𝐶𝐺𝐾𝑅𝐾! + 𝛽!𝐷𝑜𝑥 ∗ 𝐶𝐺𝐾𝑅𝐾 + 𝜀  (1) 
 
After removing the outlier data points, the quadratic model was analyzed again and to 
determine the coefficients of the parameters present in the full quadratic model equation. Finally, 
ANOVA calculations were conducted comparing the variation due to the changes in the 
parameters with the variation due to the random errors, which occurred during the 
measurements. This step is performed to determine the suitability of the model equation to fit the 
experimental data, as discussed in section 2.1.2 in chapter 02.  
According to the results obtained for the coefficient parameters and ANOVA analysis for 
the quadratic model, further modifications of the model equation have been carried out. These 
modified models were further analyzed using the same protocol until a statistically significant 
model equation was obtained where the mathematical model fits the experimental data. Non-
significant terms of the quadratic model equation were excluded using the backward elimination 
process. Analysis data of each concentration as a function of time is discussed separately. 
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5.1.1.1 Cell Viability of 10 µg/ml Nanoparticle Concentration after 24 h 
Incubation 
Cell viability data for samples number 9 and 13 were found to be outliers at 10 µg/ml 
concentration. The constructed quadratic surface model for the other observations is shown in 
Figure 5.1 below. The coefficient parameters of the quadratic mathematical model (β0 to β5) were 
calculated and found to be not statistically significant. The requirement for “significant” is P 
value (P) < 0.05.  Furthermore, the ratio between the media of square values of regression 
(MSreg) and residual (MSres) obtained from ANOVA is lower than the tabulated Fisher 
distributions (f test) Tabulated in Table B.1 (appendix B). Therefore, the mathematical model did 
not fit the experimental data. 
 
Figure 5.1 Quadratic response surface for the cell viability with respect to CGKRK and 
doxorubicin at nanoparticle concentration of 10 µg/ml 
The reduced mathematical model was constructed as, 
 𝑐𝑒𝑙𝑙  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝛽! + 𝛽!𝐷𝑜𝑥 + 𝛽!𝐷𝑜𝑥! + 𝛽!𝐶𝐺𝐾𝑅𝐾 + 𝜀    (2) 
This model became statistically significant (P < 0.05) as shown in the Table 5.2 below. 
10
50
90
130
CGKRK
10
50
90
130
DOX
Predicted Value of CELL_VIA
57.87
70.62
83.37
96.12
97 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 738.60459 246.20153 6.41 0.0160 
Error 8 307.06207 38.38276   
Corrected Total 11 1045.66667    
 
Table 5-2 Regression analysis data for the reduced model (2) for nanoparticle 
concentration of 10 µg/ml 
 
According to the parameter estimation data as shown below (Table 5.3) CGKRK was not 
a significant factor (where 𝛽!  is  not  significant).  
Variable Parameter Estimate Standard Error Type II SS F Value Pr > F 
Intercept 76.18240 15.18406 966.20612 25.17 0.0010 
CGKRK -0.06953 0.06905 38.92233 1.01 0.3434 
DOX 0.82632 0.38984 172.45089 4.49 0.0669 
DOX2 -0.00688 0.00267 254.75312 6.64 0.0328 
 
Table 5-3 Estimated coefficient parameter values for the reduced quadratic model for 10 
µg/ml nanoparticle concentration 
 
Therefore, the number of CGKRK molecules was removed from the equation, and the 
final mathematical model was obtained as, 
 𝑐𝑒𝑙𝑙  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝛽! + 𝛽!𝐷𝑜𝑥 + 𝛽!𝐷𝑜𝑥! + 𝜀     (3) 
 
This model is highly significant with respect to both, DOX and DOX2 values. The ratio 
of media of square values of regression (MSreg) and residual (MSres) is higher than the tabulated 
value (f-test). The regression analysis data and parameter estimation are shown in the Table 5.4 
and the corresponding response surface for the mathematical model represents a saddle, as 
shown in the Figure 5.2 below. 
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Table 5-4 a). Regression analysis data for the final mathematical model (3) and b). 
parameter estimation for nanoparticle concentration of 10 µg/ml 
 
Figure 5.2 Quadratic response surface for cell viability with respect to doxorubicin at 10 
µg/ml of nanoparticle concentration 
By definition, this response surfaces represents a saddle, due to the quadratic response to 
DOX concentrations. Therefore, it does not provide either minimum or a maximum critical point 
within the chosen experimental domain. Therefore, careful displacements of the experimental 
CELL_VIA
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DOX
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Analysis of Variance 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 2 699.68226 349.84113 9.10 0.0069 
Error 9 345.98440 38.44271   
Corrected Total 11 1045.66667    
Variable 
Parameter 
Estimate 
Standard 
Error Type II SS F Value Pr > F 
Intercept 68.23693 12.98319 1061.91627 27.62 0.0005 
DOX 0.93136 0.37591 235.97638 6.14 0.0351 
DOX2 -0.00778 0.00252 365.41286 9.51 0.0131 
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domain should be carried out to obtain a minimum in this particular study. Recommended 
experimental conditions provided by the calculation lie in the range of 110 to 120 molecules of 
doxorubicin and any number of CGKRK molecules, as it is not significant in this model.    
5.1.1.2 Cell Viability of 50 µg/ml Nanoparticle Concentration after 24 h 
Incubation 
Statistical analysis of cell viability responses for 50 µg/ml concentrations of iron oxide 
nanoparticles provided similar results than 10 µg/ml, as discussed in section 5.1.1. Samples 9 and 
13 were outliers, and the analysis of the mathematical quadratic model (equation 1) was 
performed without accounting for observations 9 and 13. The overall model was not statistically 
significant, according to the ANOVA results (Table B.2 in Appendix). The quadratic response 
surface for the full model is given below in Figure 5.3. 
 
Figure 5.3 Quadratic response surface for the cell viability with respect to CGKRK and 
doxorubicin at nanoparticle concentration of 50 µg/ml 
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In analogy to 10 µg/ml, the reduced mathematical model (equation 2) was also analyzed. 
According to the regression analysis data and parameter estimation data given in the Table 5.5 it 
is statistically significant without taking CGKRK into account.  
a 
 
b 
 
Table 5-5 a). Regression analysis data for the reduced mathematical model (2) and b). 
parameter estimation for nanoparticle concentration of 50 µg/ml 
 
Therefore, a third model (equation 3) was analyzed again without CGKRK in the model 
equation.  This model became highly significant for both DOX and DOX2 values hence this 
mathematical model fits the experimental domain, as proven by ANOVA analysis and represent 
in Table 5.6.  
a 
 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 3 738.60459 246.20153 6.41 0.0160 
Error 8 307.06207 38.38276   
Corrected Total 11 1045.66667    
 Variable Parameter 
Estimate 
Standard 
Error 
Type II SS F Value Pr > F 
 Intercept 76.18240 15.18406 966.20612 25.17 0.0010 
* CGKRK -0.06953 0.06905 38.92233 1.01 0.3434 
* DOX 0.82632 0.38984 172.45089 4.49 0.0669 
 DOX2 -0.00688 0.00267 254.75312 6.64 0.0328 
* Forced into the model by the INCLUDE= option 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 2 699.68226 349.84113 9.10 0.0069 
Error 9 345.98440 38.44271   
Corrected Total 11 1045.66667    
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b 
 
Table 5-6 a). Regression analysis data for the final mathematical model (3) and b). 
parameter estimation for nanoparticle concentration of 50 µg/ml 
 
The response surface for the model represents again a saddle, similar to the previous 
results. Therefore, careful displacements of the experimental domain should be carried out to 
obtain a critical minimal point for the optimization process of the iron oxide based nanoparticle 
systems. It should be noted that the solubility of the Fe/Fe3O4-nanoparticles will decrease if the 
doxorubicin loading will increase, due to the hydrophobicity of this drug (log P = 1.42, 
compared to log P = 0.58 for dopamine and log P = -5.1 for CGKRK, according to Chemdraw).  
 
 
Figure 5.4 Quadratic response surface for cell viability with respect to doxorubicin at 50 
µg/ml of nanoparticle concentration 
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Parameter Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error t Value Pr > |t| 
Intercept 1 68.23693 12.98319 5.26 0.0005 
DOX 1 0.93136 0.37591 2.48 0.0351 
DOX2 1 -0.00778 0.00252 -3.08 0.0131 
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5.1.1.3 Cell Viability of 100 µg/ml Nanoparticle Concentration with 24 h 
Incubation 
Contrary to the two previous matrices for 10 and 50 µg/ml, no outliers were observed 
when a fully quadratic model (equation 1) was applied to fitting the experimental data obtained 
with 100 µg/ml. However, the overall model was statistically not significant with P > 0.05 for 
ANOVA. Then, the experimental data were analyzed using a reduced model. Both, CGKRK and 
DOX were found to be insignificant factors in the model. Similarly, a third model with equation 
3 was also found to be not significant for iron/iron oxide nanoparticle concentrations of 100 
µg/ml. Even though the fully quadratic response surface model was not significant, it has been 
used to construct the response surface, which is shown in Figure 5.5.  
 
Figure 5.5 Quadratic response surface for the cell viability with respect to CGKRK and 
doxorubicin at nanoparticle concentration of 100 µg/ml 
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The quadratic response surface comprises a minimum. The predicated stationary point is 
66 CGKRK oligopeptides and 121 doxorubicin molecules per Fe/Fe3O4 nanoparticle. The 
tabulated data is shown in table 5.2. It is noteworthy that the value predicted for the optimal 
number of doxorubicin molecules per nanoparticle at 100 µg/ml corresponds with the highest 
observed cytotoxicities at 10 µg/ml and 50 µg/ml. At these concentration levels, statistical 
significance for linear and quadratic dependencies in the number of doxorubicins per 
nanoparticle has been achieved.  
Factor 
Critical Value 
Coded Uncoded 
CGKRK -0.282846 66.423407 
DOX 0.860735 121.315295 
Predicted value at stationary point: 62.641964 
 
Table 5-7 Coded and experimental values for the critical minimum point in quadratic 
response surface for cell viability with respect to CGKRK and doxorubicin  
 
Analysis of cell viability with each nanoparticle concentrations for 48 hours incubation 
time was also carried out in a similar manner using the full quadratic model, the reduced model 
and the third model, as denoted in equations 1, 2 and 3. For the nanoparticle concentration 10 
µg/ml and 48 h of incubation time no output data were obtained as no acceptable error term 
could be calculated during the statistical analysis. Therefore, testing of the mathematical models 
with experimental data was not possible for that concentration. For concentrations of 50 µg/ml 
and 100 µg/ml all three models were analyzed and none of the models were statistically 
significant for the given experimental domain. In both cases, the full quadratic response surface 
provided a saddle as the corresponding response surface.   
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5.1.1.4 Discussion 
Based on the analysis of the data, it is clearly evident that response surface methodology 
can be successfully used for the optimization of the composition of iron / iron oxide nanoparticle 
based drug delivery systems, as well as to evaluate their therapeutic efficacy in the cancer cell 
tests. The outcome of the statistical analysis of the data obtained from cytotoxicity tests with 
PAN02 cells (murine pancreatic cancer) is that a quadratic mathematical model was significant 
for concentrations of 10 µg/ml and 50 µg/ml and 24h of incubation time. Most interestingly, the 
model was significant with respect to the linear and quadratic numbers of doxorubicin molecules 
per Fe/Fe3O4-nanoparticle, while it was insignificant with respect to the peptide homing 
sequence CGKRK. Therefore, it is likely that the short peptide sequence CGKRK is not 
contributing to the selective uptake of the iron / iron oxide nanoparticles by the cancer cells via 
receptor mediated targeting. Rather, they are taken up by the cancer cells via a phagocytosis 
mechanism. It is noteworthy that the iron /iron oxide nanoparticle concentration did not have 
much of an effect on the therapeutic activity. Similar trends were observed with all three 
concentrations, even though 24 h of incubation time provided statistically significant responses, 
compared to the 48 h of incubation. Moreover, the doxorubicin amount on each nanoparticles 
should be in the upper range of the experimental domain, as it is suggested by the mathematical 
calculations. However, it may be also worthwhile to explore the cytotoxicity of nanoparticles 
bearing only 10 to 20 molecules of doxorubicin per nanoparticle, as suggested by the quadratic 
response. The strength of using a response surface methodology approach is that a mechanistic 
paradigm is not required for successful data analysis. It is likely that the cytotoxicity towards 
PAN02 cells at low and high loadings of Fe/Fe3O4-nanoparticles with doxorubicin (figures 5.2 
and 5.4) is caused by different biochemical mechanism. We speculate that doxorubicin, which is 
105 
 
less hydrophilic than dopamine and especially CGKRK, may cause longer retention of the 
nanoplatforms in the endosomes, whereas escape from early endosomes may be possible at lower 
doxorubicin loadings. Further experiments should be carried out in accordance with the 
predictions provided by the quadratic model. They should be conducted in a narrow experimental 
region to determine optimized parameters. The results obtained to date clearly show that the use 
of Doehlert design in experimental design processes contributes to lowering experimental costs 
by eliminating unnecessary experiments, resulting in more efficient optimization with lower 
number of experiments and lower time and materials consumption. 
5.1.2 Analysis of Secondary Cell Cytotoxicity Data 
Statistical analysis of preliminary cytotoxicity data suggest that the further cell 
experiments need to be carried out in order to find the optimized iron/iron oxide nanoparticle 
composition with CGKRK and doxorubicin. The suggestion of a new target domain by the 
statistical analysis of our first set of experimental cell cytoxicity data clearly demonstrates the 
advantage of the methodology explored here.  In using a statistical analysis method to develop 
nanoparticle-based anticancer agents to successfully treat pancreatic cancer, we were able to save 
numerous experiments, which otherwise would have to be conducted. This approach also 
provided the correct directions for the extension of the experimental domain in further studies. 
Considering all the predictions and suggestions obtained from the preliminary analysis, two 
extended Doehlert matrices were constructed and cell cytotoxicity measurements were conducted 
following the same protocols. Percentage cell viability data were obtained, which were then 
directly used for the statistical analysis in order to determine whether the new matrices represent 
the optimal conditions for the nanoparticle system for anticancer treatment. Obtained cell 
viability data are listed on the next page. (Table 5.8). 
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   Percentage	  cell	  viability	   	  	  
Sample	  
number	  
24	  hrs	   composition	  
concentration	  in	   µg/ml	   	  	  
10	   50	   100	   (cgkrk,dox)	  
3	   46	   61	   51	   104,120	  
3	   56	   58	   51	   104,120	  
3	   74	   71	   66	   104,120	  
1	   100	   98	   88	   80,80	  
2	   89	   94	   78	   128,80	  
7	   115	   103	   71	   56,120	  
20	   45	   51	   47	   80,160	  
21	   47	   40	   36	   128,160	  
22	   75	   64	   62	   152,120	  
	   	   	   	   	  
	   	   	   	  
(dox,cgkrk)	  
9	   94	   86	   69	   128,80	  
10	   78	   75	   76	   104,120	  
16	   63	   62	   66	   176,80	  
17	   84	   77	   55	   200,120	  
18	   55	   46	   41	   176,160	  
19	   74	   63	   63	   128,160	  
15	   90	   80	   76	   152,120	  
15	   52	   54	   75	   152,120	  
15	   58	   52	   81	   152,120	  
 
Table 5-8 Cell cytotoxicity data for extended Doehlert matrices depending on the 
concentration for 24 h incubation 
Three analyses were carried out for three concentrations combining all the data obtained 
for each concentration. The statistical analysis results will be discussed below. 
5.1.2.1 Percentage Cell Viability of 10 µg/ml Nanoparticle Concentration  
Similar to the preliminary data analysis, a full quadratic response surface model (equation 
1) was constructed initially and then analyzed, with the intent to determine the presence of any 
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outliers using Cook’s distance criteria (Cook’s D < 1.0). No outliers were observed for the input 
data. Then analysis of variance (ANOVA) was carried out to determine the fitness of the model 
to the experimental data by regression analysis (the ratio between the media of square values of 
regression (MSreg) and residual (MSres)) and lack of fit test (the ratio between the media of square 
values of lack of fit (𝑀𝑆!"#) and pure error (𝑀𝑆!")) compared to the tabulated Fisher 
distributions (f test). Based on the regression analysis data (Table 5.9), the overall model was not 
significant at 5% level (α = 0.05) with a P value for the model is 0.12. 
a 
 
 b 
 
Table 5-9 a) Regression analysis; b) Lack of fit test statistical output data for full quadratic 
model for 10 µg/ml nanoparticle concentration  
 
Nevertheless, as shown in the Table 5.4.b, the lack of fit test carried out at α = 0.05 gave 
a P value = 0.5356. Therefore, the quadratic model is considered to be adequate. Consequently, 
coefficient parameters (𝛽) of the quadratic model were calculated to determine the fitness of  
each term in the model. The results are recorded in the Table 5.10.  
Analysis of Variance 
Source DF Sum of Squares 
Mean 
Square F Value Pr > F 
Model 5 3447.31031 689.46206 2.22 0.1200 
Error 12 3731.63414 310.96951   
Corrected Total 17 7178.94444    
Residual DF 
Sum of 
Squares Mean Square F Value Pr > F 
Lack of Fit 8 2494.300802 311.787600 1.01 0.5356 
Pure Error 4 1237.333333 309.333333   
Total Error 12 3731.634135 310.969511   
108 
 
Parameter Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error t Value Pr > |t| 
Intercept 1 336.98304 102.91704 3.27 0.0066 
CGKRK 1 -2.10167 1.10610 -1.90 0.0817 
DOX 1 -1.94593 1.03740 -1.88 0.0852 
CGKRK2 1 0.00761 0.00467 1.63 0.1290 
DOX2 1 0.00559 0.00359 1.56 0.1457 
CGKRK_DOX 1 0.00160 0.00550 0.29 0.7765 
 
Table 5-10 Estimated coefficient parameter values for the full quadratic model for 10 µg/ml 
nanoparticle concentration 
The doxorubicin and CGKRK interaction term (DOX*CGKRK) term was not significant 
with a P value = 0.7765 and excluded from the model. DOX2 and CGKRK2 terms were marginal 
at 10% significance level. A reduced model was constructed to evaluate its fitness by omitting 
the DOX*CGKRK term. The resulting equation is given below.  
The Reduced mathematical model: 𝑐𝑒𝑙𝑙  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝛽! + 𝛽!𝐷𝑜𝑥 + 𝛽!𝐷𝑜𝑥! + 𝛽!𝐶𝐺𝐾𝑅𝐾 + 𝛽!𝐶𝐺𝐾𝑅𝐾! + 𝜀  (4) 
ANOVA calculations (Table 5.11) were conducted and the model become significant at 
10% level with P value = 0.0610.  
Analysis of Variance 
Source DF 
Sum of 
Squares 
Mean 
Square F Value Pr > F 
Model 4 3421.10009 855.27502 2.96 0.0610 
Error 13 3757.84436 289.06495   
Corrected Total 17 7178.94444    
 
Table 5-11 Regression analysis data for reduced quadratic model for 10 µg/ml nanoparticle 
concentration 
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Coefficient parameters (𝛽) of all the terms in the model are statistically significant at α = 
0.10 with coefficient of variation (R2) value of 47.65% for the model. (Term DOX has a 
marginal P value = .1066). Parameter values are shown in the Table 5.12. 
Variable 
Parameter 
Estimate 
Standard 
Error Type II SS F Value Pr > F 
Intercept 321.71591 85.29476 4112.40420 14.23 0.0023 
CGKRK -1.97120 0.97444 1182.88662 4.09 0.0642 
DOX -1.83371 0.92817 1128.23814 3.90 0.0698 
CGKRK2 0.00800 0.00432 991.21829 3.43 0.0869 
DOX2 0.00583 0.00336 868.73590 3.01 0.1066 
 
Table 5-12 Estimated coefficient parameter values for the reduced quadratic model for 10 
µg/ml nanoparticle concentration 
 
Therefore, the estimated quadratic model that represents the experimental percentage cell 
viability (Ŷ) can be written as  Ŷ = 0.0023+ 0.0698𝐷𝑜𝑥 + 0.1066𝐷𝑜𝑥! + 0.0642𝐶𝐺𝐾𝑅𝐾 + 0.0869𝐶𝐺𝐾𝑅𝐾! 
 Finally the response surface plot and contour plot for the reduced model were 
constructed and shown in Figure 5. 6 and Figure 5.7, respectively.  
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Figure 5.6 Quadratic response surface for the cell viability with respect to CGKRK and 
doxorubicin at nanoparticle concentration of 10 µg/ml for extended matrices 
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Figure 5.7 Contour plot of the cell viability with respect to CGKRK and doxorubicin at 
nanoparticle concentration of 10 µg/ml for extended matrices 
 
The response surface for the percentage cell viability with respect to doxorubicin and 
CGKRK at 10 µg/ml concentration is a minimum, as expected and predicted in the preliminary 
calculations. The minimum cell viability that can be obtained using the nanoparticle at this 
concentration is 56.1%, and the composition of the nanoparticle system should be maintained at 
156 <DOX<159 and 122 < CGKRK < 125.  
Predicted Value of CELL_VIA 60.06 68.32 76.58 84.85 93.11
101.38 109.64 117.90 126.17 134.43
DOX
75
109
143
176
210
CGKRK
50 79 108 136 165
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5.1.2.2 Percentage Cell Viability of 50 µg/ml Nanoparticle Concentration  
The same statistical analysis procedure was conducted for the nanoparticle concentration 
50 µg/ml, as descried in section 5.1.2.1. Initially, the full quadratic response surface model 
(equation 1) with DOX and CGKRK terms was analyzed using Cook’s distance criteria to 
eliminate any outliers. No outliers were observed for the data obtained using 50µg/ml 
concentration. Then ANOVA calculations were carried out to determine the fitness of the model 
to the experimental data by regression analysis and lack of fit test. The overall model was 
statistically significant at the 5% level with a P value =0.014 from regression analysis (shown in 
Table 5.13.a).  
a. 
 
b. 
 
Table 5-13 a) Regression analysis and b) Lack of fit test statistical output data for full 
quadratic model for 50 µg/ml nanoparticle concentration  
 
Moreover, the lack of fit test was conducted at the same significance level (α = 0.05) and 
the model is adequate with a P value = 0.4743 (data shown in Table 5.13.b). Next, coefficient 
Analysis of Variance 
Source DF 
Sum of 
Squares 
Mean 
Square F Value Pr > F 
Model 5 3708.65874 741.73175 4.62 0.0140 
Error 12 1927.61904 160.63492   
Corrected Total 17 5636.27778    
Residual DF 
Sum of 
Squares Mean Square F Value Pr > F 
Lack of Fit 8 1346.952370 168.369046 1.16 0.4743 
Pure Error 4 580.666667 145.166667   
Total Error 12 1927.619036 160.634920   
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parameters (𝛽) were calculated (shown in Table 5.14.). Similar to 10µg/ml doxorubicin and 
CGKRK, the interaction term was not statistically significant and hence excluded from the 
model.  
Parameter Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error t Value Pr > |t| 
Intercept 1 105.24831 82.63833 1.27 0.2269 
CGKRK 1 0.32977 0.88815 0.37 0.7169 
DOX 1 -0.59502 0.83299 -0.71 0.4887 
CGKRK2 1 -0.00123 0.00375 -0.33 0.7477 
DOX2 1 0.00181 0.00288 0.63 0.5420 
CGKRK_DOX 1 -0.00104 0.00442 -0.24 0.8169 
 
Table 5-14 Estimated coefficient parameter values for the full quadratic model for 50 µg/ml 
nanoparticle concentration 
 
Experimental data were fitted again to the reduced model shown in equation 4. The 
model is highly significant at the 5% significance level with a P value = 0.0049 with a coefficient 
of variation value 65.8% for the model. The data is shown below in Table 5.15. 
Analysis of Variance 
Source DF 
Sum of 
Squares 
Mean 
Square F Value Pr > F 
Model 4 3708.64940 927.16235 6.25 0.0049 
Error 13 1927.62838 148.27911   
Corrected Total 17 5636.27778    
 
Table 5-15 Regression analysis data for reduced quadratic model for 50 µg/ml nanoparticle 
concentration 
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The total variation in the residual can be explained by the fitted reduced model. When 
coefficient parameters were calculated (Table 5.16) for the model CGKRK and CGKRK2 terms 
were significant at α = 0.05, but become marginal at α= 0.1. 
Variable 
Parameter 
Estimate 
Standard 
Error Type II SS F Value Pr > F 
Intercept 289.95829 61.08923 3340.57924 22.53 0.0004 
CGKRK -1.17785 0.69791 422.33803 2.85 0.1153 
DOX -1.93561 0.66477 1257.11611 8.48 0.0121 
CGKRK2 0.00419 0.00309 272.37109 1.84 0.1984 
DOX2 0.00605 0.00241 934.32361 6.30 0.0261 
 
Table 5-16 Estimated coefficient parameter values for the reduced quadratic model for 50 
µg/ml nanoparticle concentration 
 
Therefore estimated quadratic model that represents the experimental percentage cell 
viability (Ŷ) can be written as  
 Ŷ = 0.0004+ 0.0121𝐷𝑜𝑥 + 0.0261𝐷𝑜𝑥! + 0.1153𝐶𝐺𝐾𝑅𝐾 + 0.1984𝐶𝐺𝐾𝑅𝐾! 
 
Finally the response surface plot and contour plot for the reduced model were constructed 
and shown in Figure 5. 8 and Figure 5.9, respectively. 
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Figure 5.8 Quadratic response surface for the cell viability with respect to CGKRK and 
doxorubicin at nanoparticle concentration of 10 µg/ml for extended matrices 
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Figure 5.9 Contour plot of the cell viability with respect to CGKRK and doxorubicin at 
nanoparticle concentration of 50 µg/ml for extended matrices 
 
The response surface for the percentage cell viability with respect to doxorubicin and 
CGKRK at 50 µg/ml concentration is a minimum, as expected and predicted in the preliminary 
calculations. The minimum cell viability that can be obtained using the nanoparticle at this 
concentration is 52.3% and the composition of the nanoparticle system should be maintained at 
158<DOX<160 and 138 < CGKRK < 143. Compared to the 10 µg/ml, the reduced model for 50 
µg/ml is highly significant with a P value = 0.0049 , a larger R2 value and a lower cell viability 
as well. 
 
Predicted Value of CELL_VIA 56.36 64.72 73.09 81.45 89.82
98.19 106.55 114.92 123.28 131.65
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5.1.2.3 Percentage Cell Viability of 100 µg/ml Nanoparticle Concentration  
For the 100 µg/ml cell viability data, the same experimental procedure has been carried 
out. Initially, the full quadratic model was fitted to check the presence of any outliers. No 
outliers were observed. Then the regression analysis and lack of fit tests were performed to 
determine the fitness of the model to the experimental data. According to the regression analysis 
data, the overall model was not significant with a very high P value (0.3790) for the model. The 
lack of fit test was conducted at α=0.05 and gave very low P value which is 0.0436. Therefore, 
the model is not adequate to conduct further analysis. It is also found that none of the terms in 
the model was significant. (P value> 0.05). 
Backward elimination process was used to exclude the non-significant terms in model. 
DOX was the only significant factor with a P value=0.03. Therefore, the model is unable to 
produce a minimum or maximum for the iron/iron oxide nanoparticle concentration of 100 
µg/ml. The reduced model for this concentration can be written as, 
 𝑐𝑒𝑙𝑙  𝑣𝑖𝑎 = 𝛽! + 𝛽!𝐷𝑂𝑋 ++𝜀     (5) 
 
In the preliminary analysis of the 100 µg/ml concentration, the minimum cell viability 
was obtained even though it is not statistically significant for both doxorubicin and CGKRK. 
When the nanoparticle composition is changed during the extended matrices, the experimental 
domain that is of interest has been moved away from the original region. Therefore, it can be 
assumed that the active experimental domain for the 100 µg/ml concentration may not lie within 
the extended matrix. The nanoparticle composition that gives the minimum cell viability was in 
the predicted value range, as mentioned in Table 5.7. In addition, the cell cytotoxicity obtained 
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for this concentration may be due to the high iron nanoparticle concentrations, rather than due to 
the cytotoxic activity of doxorubicin or CGKRK.   
5.2 Discussion 
Based on the statistical analysis carried out for both preliminary and extended matrices. it 
is clear that application of response surface methodology is a very suited to discover the proper 
composition of doxorubicin and CGKRK at the surface of the Fe/Fe3O4 carrier nanoparticles. 
Using Doehlert methodology, we were successful in developing an promising candidate for an 
anticancer agent for treatment of pancreatic cancer. Based on the preliminary analysis, we 
predicted that the initial Doehlert matrices should be extended to higher values of doxorubicin, 
where the number of doxorubicin molecules per nanoparticle should be higher than 120. Since 
the CGKRK was statistically insignificant in the model in the initial calculations CGKRK any 
CGKRK amounts can be used but the cell viability is comparatively to with number of CGKRK 
molecules are higher than 85. But CGKRK should be presence on the nanoparticles for the 
observed cell cytotoxicity. Extending the cell viability studies with newly synthesized iron/iron 
oxide nanoparticle systems with new doxorubicin and CGKRK compositions according to the 
preliminary data gave very good cytotoxicity activity, as predicted. Moreover, it is observed that 
the cell cytotoxicity of the nanoparticle systems was reduced when the doxorubicin amount was 
increased after 160 doxorubicin molecules per nanoparticle. Based on our analysis, both 10 
µg/ml and 50 µg/ml gave very good statistical data assuming quadratic response surfaces. 
Minima at 156-160 doxorubicin molecules per nanoparticle for the percentage cell viability of 
Pan02 cells were found. From the two concentrations, 50 µg/ml gave the best results with a very 
low P value of 0.0049. 10 µg/ml resulted in acceptable results with a P value of 0.06. In both 
cases, the reduced models successfully represented the experimental data obtained from the MTT 
119 
 
assays. Therefore, the constructed mathematical models were fitted to the experimental region. 
Proper iron/iron oxide nanoparticle compositions are obtainable from this analysis, which ensure 
maximal therapeutic effects on Pan02 cells. Based on the data at both concentrations, very 
similar nanoparticle compositions were calculated: the number of doxorubicin molecules should 
be varied around 156 – 160 and CGKRK molecules around 125-140. Since CGKRK parameters 
give marginal statistical significances in both cases, further studies should be carried out in order 
to determine whether CGKRK truly contribute to the synergistic activity with doxorubicin or 
whether CGKRK can be removed from the system. It is also noteworthy that the predicted iron 
oxide nanoparticle compositions with required doxorubicin and CGRKR composition does show 
very minimum toxicity in the non-cancerous STO cells during the MTT assays.  
5.3 Conclusion 
Statistical analysis using response surface methodology was successfully applied in 
optimizing the composition of an iron / iron oxide nanoparticle based drug delivery system for 
doxorubicin. Statistical analysis shows that more than 50% of the cancerous Pan02 cells can be 
killed within 24 and 48 hours using low iron/iron oxide nanoparticle concentrations. Response 
surface methodology is a very promising strategy in developing potent therapeutic agents for 
treating pancreatic cancer. Iron / iron oxide nanoparticles proved to be suitable carriers of 
doxorubicin, potentiating the pharmacological action of this well-known topoisomerase II 
inhibitor. Further experiments need to be carried out to explore the relevance of the tumor-
homing peptide sequence CGKRK in the system and to further maximize the therapeutic activity 
of the nanoparticle system. 
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Appendix A - Spectral Data 
 
 a. 
 
b. 
 
Table A-1 a) Fe(II) concentration and b) CGKRK concentration present on each iron/iron 
oxide samples determined from ICP-OES measurements 
 
Iron/iron oxide 
nanoparticle sample 
Fe(II) concentration 
(mg/L) 
1 68 
3 64 
5 70 
6 68 
7 70 
Iron/iron oxide 
nanoparticle sample 
CGKRK 
concentration (mg/g) 
1 23.56 
3 24.6 
5 21.24 
6 22.56 
7 23.76 
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Figure A.1 1H NMR of the intermediate product of dopamine ligand 3.5 
 
 
Figure A.2 1H NMR of the ligand 3.5 in DMSO 
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Figure A.3 13C NMR of the ligand 3.5 in DMSO 
 
 
Figure A.4  MS-API of coupling product 3.9 
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Figure A.5 MS-API of coupling product 3.10 
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Appendix B - Statistical Data 
Calculated data for section 5.1.1.1 
Analysis of Variance 
Source DF 
Sum of 
Squares 
Mean 
Square F Value Pr > F 
Model 5 739.21388 147.84278 2.89 0.1141 
Error 6 306.45279 51.07546   
Corrected Total 11 1045.66667    
 
Table B-1 Regression analysis of the full quadratic model represent in the equation 1 
 
 
 
Figure B.1 Fit diagnostics for cell viability for 10 µg/ml for 24 h 
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Calculated data for section 5.1.1.2 
Analysis of Variance 
Source DF 
Sum of 
Squares 
Mean 
Square F Value Pr > F 
Model 5 739.21388 147.84278 2.89 0.1141 
Error 6 306.45279 51.07546   
Corrected Total 11 1045.66667    
 
Table B-2 Regression analysis of the full quadratic model represent in the equation 1 
 
 
 
Figure B.2 Fit diagnostics for cell viability for 50 µg/ml for 24 h 
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Figure B.3 Fit Diagnostics for cell viability 10 µg/ml for 24 h in section 5.1.2.1 
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Figure B.4 Fit Diagnostics for cell viability 10 µg/ml for 24 h in section 5.1.2.2 
  
